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ABSTRACT 
Maria Agostina Santoro: Obesity, hyperinsulinemia, the insulin and insulin-like growth factor 1 receptors, 
and risk of colorectal cancer 
(Under the direction of P. Kay Lund)  
 
 Insulin resistance and hyperinsulinemia associated with obesity or type 2 diabetes are strongly 
associated with increased risk of colorectal cancer (CRC). Elevated plasma insulin can increase the levels 
of “free” insulin-like growth factor 1 (IGF1) in the circulation. Both insulin and IGF1 can bind and 
activate the insulin receptor (IR) or the related IGF1 receptor (IGF1R). IGF1R is traditionally viewed as a 
major mediator of growth and anti-apoptosis and has been linked to cancer. IR is expressed as two 
isoforms, IR-A and IR-B. IR-A promotes growth of fetal and possibly cancer cells, while IR-B mediates 
the metabolic actions of insulin and promotes differentiation in some tissues. However, the specific roles 
of IGF1R, IR-A, and IR-B in colon physiology and tumorigenesis are unclear. This dissertation combined 
translational and pre-clinical approaches to explore the roles of IGF1R and IR in colorectal adenoma risk, 
tumorigenesis, and reduced apoptosis of genetically damaged colonocytes during obesity and 
hyperinsulinemia. Our studies showed that increased IR-A:IR-B ratio due to decreased IR-B mRNA 
predicted colorectal adenomas in patients with elevated plasma insulin. In a mouse model of 
inflammation-induced CRC, genetic deletion of IR in colon epithelial cells (CECs) enhanced tumor 
number in vivo and tumor cell growth in vitro and this was associated with enhanced IGF1-induced AKT 
activation. Obesity/hyperinsulinemia resulted in reduced apoptosis of CECs in normal colon after 
radiation-induced DNA damage. Surprisingly, loss of IGF1R in CECs had no effects on apoptosis, but 
loss of IR dramatically increased apoptosis of genetically-damaged CECs. However, IR loss did not 
prevent the anti-apoptotic effects of obesity/hyperinsulinemia. Overall, this dissertation provides novel 
evidence that maintained IR expression and function may protect against early stage colon tumorigenesis.
iv 
Since IR-B expression is reduced in colon tumors in mice and normal mucosa of hyperinsulinemic 
patients with adenomas, we propose that in the colon, IR-B normally attenuates the proliferative, anti-
apoptotic, or tumorigenic actions of IGF1R or IR-A. Our studies suggest that therapeutic strategies to 
increase or maintain IR-B expression may improve prevention of CRC, particularly when IR-B function 
is impaired as occurs during insulin resistance associated with obesity or type 2 diabetes. 
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CHAPTER 1: INTRODUCTION TO COLON PHYSIOLOGY, COLORECTAL CANCER, THE 
INSULIN/IGF SYSTEM, OBESITY, AND APOPTOSIS 
 
The colonic epithelium 
Structure and function 
In humans, the colon consists of ascending, transverse (proximal colon), and descending (distal 
colon) segments and the rectum 
1
. Absorption of fat, carbohydrates, and proteins occurs primarily in the 
small intestine and remaining luminal contents flow into the proximal colon which reabsorbs fluids and 
electrolytes 
1-3
. The proximal colon is also the primary site for absorption of short-chain fatty acids 
(SCFAs) synthesized by bacterial fermentation of carbohydrates that were not absorbed in the small 
intestine 
1,4
. The distal colon also produces SCFAs but at much lower levels due the decreased 
carbohydrate availability 
4
. The main function of the distal colon is to desiccate stool and store it until 
propelled into the rectum for expulsion 
1
.  
The colon has a tubular structure with an inner space called lumen. The wall of the colon is 
composed of four main layers: mucosa (which is the closest to the lumen), submucosa, muscle layer or 
muscularis propria, and serosa (Figure 1.1A). The latter constitutes the outer layer of the intestine but is 
difficult to visualize by histology. The mucosa consists of an epithelial layer known as the colonic 
epithelium, an underlying stromal connective tissue termed lamina propria, and the muscularis 
mucosa, a thin layer of smooth muscle cells (Figure 1.1A) 
1
. The colonic epithelium consists of a single 
layer of columnar epithelial cells, which form invaginations or “crypts” that extend down towards the 
muscularis mucosa. Current views indicate that the base of the crypts harbors stem and progenitors cells, 
which divide as they migrate up the crypt giving rise to three main terminally differentiated cell lineages:  
enteroendocrine cells, goblet cells, and colonocytes (Figure 1.1B) 
5
. Colonocytes and goblet cells are the
2 
most abundant cell types, constituting ~25% and ~75%, respectively, of the total cells per crypt 
6
. 
Enteroendocrine cells secrete various peptide hormones and goblet cells secrete mucus 
5
. Colonocytes are 
primarily absorptive but secrete chloride ions during diarrhea, which is accompanied by secretion of 
potassium ions by goblet cells leading to water release into the lumen 
7
. Once differentiated cells reach 
the surface epithelium, they undergo detachment-mediated cell death (anoikis) and are shed into the 
lumen 
5
.  
 
Colonic epithelial stem cells and their niche 
Renewal of the human colonic epithelium occurs every 3-8 days 
8
. Maintenance of the colon 
epithelial integrity and constant renewal requires highly active proliferation, which is driven by a small 
population of colonic epithelial stem cells (CESCs) located at the base of the crypts (Figure 1.1B). 
Current views indicate that a stem cell gives rise to two daughter cells in a process called asymmetric 
division, in order to renew itself and give rise to a transient amplifying progenitor cell that will continue 
to divide before they terminally differentiate 
9
. Therefore, stem cells are characterized by their ability to 
self-renew, give rise to all other differentiated cell types (multipotency), and live for very long periods of 
time (longevity) 
9
. In 1974, the existence of two intestinal stem cell (ISC) populations was proposed based 
on studies in the small intestine: crypt base columnar (CBC) cells which actively divide and reside at the 
very base of the crypt and a slowly-cycling, label-retaining cell (LRC) population located immediately 
above CBCs at approximately cell position 4 from the crypt base, termed “+4” 10,11. In the late 2000s, a 
number of putative markers for CBCs and +4 stem cells have been identified in the mouse small intestine, 
the first being the leucine-rich-repeat-containing G-protein-coupled receptor 5 (Lgr5) 
12
. However, the 
specificity of these markers appears to be complex, as studies showed that CBCs can express proposed 
markers of +4 and vice versa 
13
. Stem cells in the colon have been significantly less well characterized 
than in the small intestine. Proposed CESC markers include Lgr5 
12
, Musashi-1 (Msi-1) 
14
, aldehyde 
dehydrogenase 1 (Aldh) 
15
, leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1) 
16
, and high 
levels of sex determining region Y-box 9 (Sox9) 
17
.    
3 
Surrounding the colonic crypts in the lamina propria are pericryptal myofibroblasts (Figure 1.1B), 
which are considered to be a key component of the stem cell niche 
18
. These mesenchymal myofibroblasts 
are thought to contribute to differentiation by secreting bone morphogenetic protein (Bmp) signals that 
are induced by Indian hedgehog (Ihh) signals from colonocytes (Figure 1.1B) 
19
. Myofibroblasts are also 
thought to provide CESCs with Wnt signals that are important for proliferation but this is based on the 
fact that mouse colon crypts need exogenous Wnt to grow in culture 
20,21
. Notch ligands produced by 
epithelial cells at the crypt base are also involved in maintaining the balance between proliferation and 
differentiation in the colon (Figure 1.1B) 
22,23
. This has been directly shown by a recent mouse study 
which indicated that a subpopulation of crypt goblet cells marked by cKit is regulated by Notch and 
secretes epidermal growth factor (EGF) to support Lgr5+ stem cells 
22
.  
 
Colorectal cancer (CRC) 
Colorectal cancer (CRC) is the third most common cancer in men and the second in women 
worldwide 
24
. In the United States, CRC is the second leading cause of cancer death despite the decline in 
incidence and mortality over the last 30 years 
16,17
. Risk factors include being a male, family history, 
inflammatory bowel disease, diabetes, obesity, and physical inactivity 
17
. Smokers and individuals who 
have one or more alcoholic drinks per day are at increased risk for CRC 
25,26
. A number of 
epidemiological studies have linked consumption of red and processed meats to CRC risk, but these 
associations remain weak and unclear 
27
 . CRC risk in the context of obesity and diabetes will be reviewed 
in more detail in later sections. The majority of CRCs are sporadic, but some can result from inherited 
germline mutations. The most common of these is a mutation in the adenomatous polyposis coli (APC) 
gene, which encodes a tumor suppressor protein that normally inhibits Wnt/β-catenin signaling 28. 
Patients with germline APC mutation develop familial adenomatous polyposis (FAP), a pre-cancerous 
disease that usually progresses to CRC. Other genes and pathways linked to CRC are reviewed below. 
 
4 
Models of CRC initiation and progression 
Aberrant crypt foci (ACF) are thought to be the earliest precursor of CRC, usually resulting from 
a mutation that causes inactivation APC 
29
. Mutated APC leads to genetic instability which favors the 
occurrence of mutations in other genes such as the oncogene KRAS and the tumor suppressor complex 
SMAD2/4 
30,31
, causing the formation of an adenoma. RAS protein is downstream of the growth-
promoting epidermal growth factor receptor (EGFR), and monoclonal antibodies against EGFR are 
currently being used in the clinic to treat advanced CRC 
32
. However, this therapy was shown to be 
ineffective in patients whose tumors carry mutated KRAS 
33
. Progression from adenoma to malignant 
adenocarcinoma is associated with loss-of-function mutations in other genes including the tumor 
suppressor p53 
34
. This model of genetic alterations during the progression from normal colonic mucosa 
to adenocarcinoma is illustrated in Figure 1.2 and was originally proposed by Fearon and Vogelstein in 
1990 
35
. However, it is now known that CRCs are much more heterogeneous and significant efforts are 
being made to define CRC subtypes based on the involvement of multiple pathways that lead to genomic 
instability 
36-40
. These include microsatellite instability (MSI), epigenetic modifications in genes involved 
in mismatch repair (MMR), CpG island methylator phenotype (CIMP), and mutations in the oncogenes 
KRAS and BRAF 
38-40
. These studies showed that MMR-proficient (unaltered MMR genes) tumors with 
mutations in KRAS or BRAF genes are associated with poorer survival outcome than MMR-proficient 
tumors without  KRAS and BRAF mutations 
40
.  In all these mechanisms of colorectal carcinogenesis, the 
common denominator is the accumulation of DNA damage that leads to mutations and allows the cell to 
acquire cancerous potential. 
 
Cancer stem cells 
Tumors are heterogeneous lesions containing cells of different phenotypes and genotypes. It was 
originally thought that any cell within a tumor is able to initiate and sustain growth of new tumors. The 
cancer stem cell (CSC) theory, on the other hand, proposes that only a small subset of cells within a tumor 
has the proliferative capability of tumor formation and propagation 
41
. Evidence for the existence of CSCs 
5 
was initially documented in leukemia 
42,43
. Presence of CSCs was later shown in solid tumors of the breast 
and the brain 
44,45
. These studies involved transplantation of human tumor cells in immunodeficient mice 
and the observation that only a small fraction of these cells was able to grow tumors or yield tumors when 
surgically transplanted 
44,45
. The growth characteristics of these cells resembled that of stem cells. CD133 
has been shown to mark CSCs in the brain given that CD133-positive cancer cells had the ability to 
originate tumors, while CD133-negative cells did not 
45
. In 2007, two studies provided evidence that 
CD133+ was a putative marker of cancer stem cells in the colon 
46,47
. In the same year, another study 
reported that a subpopulation of cells from primary CRC tissue which expressed high levels of epithelial 
cell adhesion molecule (EpCAM) and was positive for CD44 was able to initiate tumors in 
immunodeficient mice 
48
.   
More recently, the development of stem cell reporter models have permitted further identification 
of tumor-initiating stem cells in the intestine. Clevers’ group used an Lgr5-EGFP stem cell reporter 
mouse crossed with a conditional Apc knockout (KO) mouse to provide evidence that Lgr5-positive stem 
cells represent a tumor-initiating population 
49
. This study revealed that a subset of adenoma cells 
expressing Lgr5 was able to form adenomas and give rise to multiple cell types as well as additional 
Lgr5-positive cells 
49
. In line with this evidence, other reports showed that human colon carcinomas were 
enriched for a stem-like cell population that expressed Lgr5 
50,51
.  Furthermore, a recent study by Powell 
et al. demonstrated that loss of one Apc allele in colonic progenitors expressing the stem cell marker Lrig1 
led to formation of distal adenomas in mice 
52
. 
Additional evidence for the involvement of the stem cell niche in colorectal tumorigenesis is 
supported by studies linking regulators of crypt cell proliferation and differentiation such as Wnt, Notch, 
and BMP to CRC 
21,23
. Constitutive Wnt activation leads to accumulation of nuclear β-catenin, which 
activates transcription of mediators of cell proliferation such as cMyc and CyclinD1 
53,54
. Notch is highly 
expressed in human CRC cell lines and in mouse colon tumors and has been linked to metastasis, 
transepithelial migration, and tumor neovascularization 
23
. Interestingly, two recent studies showed that 
6 
BMP signaling, which normally inhibits proliferation to promote differentiation, acquires pro-tumorigenic 
and pro-invasive roles when SMAD4 expression is lost in CRC cells 
55,56
. 
Nevertheless, the cancer stem cell theory has been a topic of controversy due to the high degree 
of heterogeneity among patients and variation in laboratory assays, which hindered validation of cancer 
stem cell markers 
57,58
. In fact, a recent study showed that activation of intestinal NFκB, a transcription 
factor involved in cell survival and inflammation, causes differentiated cells to acquire a stem-like 
phenotype and tumorigenic properties 
59. This “dedifferentiation” resulted from enhanced Wnt/β-catenin 
signaling induced by NFκB 59. This evidence does not disprove the CSC model but rather supports the 
concept of “bidirectional interconversion” between stem cells and non-stem cells that can initiate tumors 
57,59
.            
 
Inflammation and CRC 
 An important contributor to colorectal carcinogenesis is the presence of chronic inflammation. 
This has been established by numerous studies showing increased CRC risk in patients with inflammatory 
bowel disease (IBD) and accelerated tumor development in mouse models of CRC where mucosal 
inflammation is induced 
60
.    
During chronic inflammation, constant production of reactive oxygen species (ROS) can be 
mutagenic and lead to DNA damage favoring carcinogenesis 
61
. In humans, elevated levels of pro-
inflammatory interleukin-12 (IL-12) in normal rectal mucosa were associated with presence of colorectal 
adenomas 
62
. Cytokines or inflammatory mediators implicated in growth of colorectal tumors, metastasis, 
and poor prognosis are signal transducer and activator of transcription 3 (STAT3), cyclooxygenase-2 
(COX-2), tumor necrosis factor-α (TNF-α), NFκB, and the downstream interleukin-6 (IL-6) 59,63,64.  
 Obesity and high fat diet (HFD) have been strongly linked to inflammation. It is well established 
that adipocytes are a main source of pro-inflammatory cytokines such as TNF-α and IL-6 during obesity 
65
. However, there is increasing evidence that obesity-associated inflammation occurs in the intestine of 
mice and humans 
66
. For example, mice fed a HFD showed increased expression of TNF-α mRNA and 
7 
NFκB activation relative to mice fed a low fat diet 67. Particularly, TNF-α mRNA levels strongly and 
positively correlated with body weight gain, fat mass, and plasma glucose. Elevated intestinal TNF-α 
preceded weight gain and adverse metabolic consequences of obesity such as elevated plasma insulin 
67
. 
Similar results were obtained by a more recent study, where diet-induced obesity led to increased mRNA 
expression of TNF-α and interleukin-18 (IL-18) in the mouse colon 68.  
Current views support a role for the microbiota in inducing intestinal inflammation during 
obesity. Obesity induces changes in the gut microbial composition and promotes activation of the pro-
inflammatory toll-like receptor 4 (TLR4) 
69,70
. In germ-free mice, HFD feeding does not induce obesity 
and does not increase intestinal TNF-α 67,71. Colonization of germ-free NFκB-EGFP reporter mice with 
fecal slurries from HFD-fed mice activated the reporter, demonstrating that fecal contents, which include 
microbiota, were sufficient to induce inflammation 
67
. Furthermore, a recent study using mice with 
mutated K-ras showed that fecal transfer from HFD-fed donors with small intestinal tumors to healthy 
recipients fed a standard diet was sufficient to induce tumors in their small intestine 
72
. This effect was 
blocked by antibiotics, indicating that gut microbes play a key role in promoting obesity-associated 
cancer 
72
.   
Based on the links between obesity, inflammation, and colorectal tumorigenesis, a topic of 
interest to this dissertation is how signaling pathways that are altered during obesity play a role in CRC 
risk in the context of obesity-associated inflammation.      
                  
Mouse models of CRC 
  Both genetic and chemically-induced models of colorectal carcinogenesis are typically used in 
rodents. The Apc
Min/+
 mouse model carries a heterozygous mutation on the Apc gene and relates to FAP 
in humans. This genetic mouse model was discovered in 1990 by forward genetics, where ethyl-
nitrosoure-induced mutagenesis led to numerous intestinal adenomas, and this mutation was named 
multiple intestinal neoplasia (MIN) 
73
. Two years later, it was found that the MIN phenotype was caused 
by a nonsense mutation in one allele of the Apc gene, which resulted in a truncated protein 
74
. The 
8 
Apc
Min/+
 mouse represents a good animal model to study adenomas, since somatic mutations on the APC 
gene usually occur in human colorectal adenomas and CRC. However, a limitation of this mouse model is 
that it develops many adenomas in the small intestine and relatively few adenomas in the colon. This 
contrasts with human FAP, where polyposis occurs in the colon. There are also chemically-induced 
models of CRC (Figure 1.3). Administration of azoxymethane (AOM) in rodents offers one better 
system to study non-hereditary, sporadic CRC 
75
. AOM is a chemical agent which, when given to animals 
via 4-6 weekly intraperitoneal injections, can induce colon tumors (Figure 1.3 A). AOM travels through 
the bloodstream to the liver, where it gets hydroxylated and secreted into the bile for delivery in the 
intestine, where it gets further metabolized by the microbiota 
75
. The activated metabolite causes base 
mismatches in DNA which promotes formation of colorectal tumors, particularly on the mid to distal part 
of the colon 
75
. Unlike Apc
Min/+
 mice, AOM-treated animals develop tumors specifically in the colon and 
rectum, providing an advantage in terms of similarity to human disease. However, AOM-induced tumor 
formation can take as long as 5 months and susceptibility to AOM doses and number of injections 
required differ across different mouse strains. In our hands, the AOM model as applied to mice on the 
C57BL/6 background has proved problematic. Mice either do not develop tumors or develop very few 
tumors, making the model difficult to use if attempting to define interventions or genetic modifications 
that reduce tumorigenesis. Doses and numbers of AOM injections that yield tumors in C57BL/6 mice 
have resulted in liver toxicity and often unacceptable death rates. This has been particularly true in 
animals fed HFD, which was tested due to our interest in evaluating the role of obesity in colon 
tumorigenesis. Combined treatment with AOM and dextran sodium sulfate (DSS), a polysaccharide 
known to induce mucosal damage and inflammation in the colon, was shown to dramatically accelerate 
tumor development so that colon tumors are reliably observed at 2.5 months after AOM administration 
75
. 
This model consists of a single AOM injection and 3 DSS treatments (5-7 days long), each alternated 
with a 2-week recovery period (Figure 1.3 B). Like in the AOM model, tumors are seen primarily in the 
mid to distal colon and rectum, and rarely in the proximal colon. The AOM-DSS model was initially 
developed to model tumorigenesis in chronic inflammation as occurs in patients with ulcerative colitis 
9 
(UC) 
76
. However, because of its reliability, this model is widely used and is used in this dissertation to 
test the effects of loss of the insulin receptor (IR) on tumor development.   
 
The insulin/IGF system 
Ligands and receptors  
The insulin/insulin-like growth factor (IGF) system comprises three ligands, insulin, IGF1, and 
IGF2, and two receptors, insulin receptor (IR) and IGF1 receptor (IGF1R) (Figure 1.4 A). IGF1R is 
expressed at high levels in most, if not all, tissues in the body, while IR expression is most predominant in 
skeletal muscle, liver, and adipose tissues in adults 
77
. Traditional views consider IGF1R as a key 
mediator of the trophic and pro-tumorigenic actions of IGFs and IR as a mediator of the metabolic actions 
of insulin 
78-81
. Although it will not be further discussed here, a receptor specific for IGF2 (the IGF2R or 
mannose-6 phosphate receptor) also exists and it is thought to serve as a “sink” to clear IGF2 and 
attenuate its signaling 
82
. IR and IGF1R belong to the family of receptor tyrosine kinases, which are 
located at the cell membrane. These receptors consist of two extracellular or “α” subunits, which 
represent the ligand-binding domain, and two intracellular or “β” subunits, which have tyrosine kinase 
activity and auto-phosphorylate each other upon activation by ligand binding. In humans, the gene 
encoding IR (INSR) is located on chromosome 19 and the IGF1R gene in chromosome 15. Both genes 
derive from a common ancestor gene and their proteins share a high degree of structural homology: 64-
67% in the extracellular subunit and 84% in the intracellular tyrosine kinase subunit 
83
. As a result, insulin 
and IGF1 have the ability to bind both IR and IGF1R. IR has higher affinity for insulin than IGFs and 
IGF1R has higher affinity for IGFs than insulin. Therefore, at normal physiological concentrations, each 
ligand activates its “preferred” receptor 84. However, elevated concentrations of insulin can bind the 
IGF1R and elevated levels of IGFs or “free” IGFs (not bound to IGF binding proteins) can activate IR.   
During evolution of mammals, the IR gene acquired a 36-nucleotide exon and the ability to skip 
this exon by alternative pre-mRNA splicing 
85,86
. In 1985, the human IR cDNA was cloned by two 
different research groups and they each predicted the size of the protein to be 1,382 and 1,370 amino 
10 
acids 
87,88
. Four years later, it was found that this 12-amino acid difference corresponded to exon 11, 
which was present or absent depending on the tissue and the developmental stage 
89
.  These two IR 
isoforms resulting from alternative splicing were termed IR-A and IR-B (Figure 1.4 B). IR-A lacks exon 
11, is highly expressed in the fetus and in cancer cells, and is an isoform that binds IGF2 as well as 
insulin with high affinity 
90-92
. IR-B, which is only present in mammals, includes exon 11, binds primarily 
to insulin, and its highest expression has been reported in insulin target tissues such as liver, muscle, and 
adipose tissue 
93-95
. IR-B has therefore been associated with a major role in mediating the metabolic 
actions of insulin, and more recent evidence, including evidence from our laboratory, has linked IR-B to 
differentiation of some tissues 
86,96,97
. 
 
Hybrid receptors and ligand specificity 
 The high structural homology of IGF1R and IR can lead to the formation of hybrid receptors 
(HRs), which gives the insulin/IGF system an extra level of complexity 
98
. These HRs form when one 
hemireceptor (an α and a β subunit) of IGF1R heterodimerizes with a hemireceptor of IR. Both IR-A and 
IR-B can heterodimerize with IGF1R 
99
, making five possible combinations of receptors (Figure 1.5A). 
Significant efforts have been made to investigate the ligand binding affinities of these receptors in vitro 
and the data are summarized in Figure 1.5A 
99-103
. IGF1R and the hybrids HR-A and HR-B bind primarily 
to the IGFs but can bind to insulin at elevated concentrations. IR-A and IR-B have a similar binding 
affinity for their main ligand insulin, but IR-A binds much more strongly to the IGFs, especially IGF2, 
than does IR-B.  
 The function and signaling of HRs remain unclear, but their expression has been found to be 
elevated in cancer 
77
. The formation of HR-A or HR-B in a particular tissue depends on the abundance of 
IR-A and IR-B. As a result, during fetal development and carcinogenesis where IR-A is highly expressed, 
HR-A formation may allow insulin to crosstalk with IGF1R signaling 
77,99
. However, in normal 
differentiated cells where IR-B is more highly expressed, HR-B may attenuate IGF1 signaling through 
IGF1R to limit proliferative effects 
77,99
. Furthermore, signaling through HRs is thought to be dictated by 
11 
the type of HR that predominates. In vitro studies using a variety of cell lines showed that in cells 
expressing predominantly HR-A, IGFs promoted cell proliferation and migration more potently than in 
cells expressing primarily HR-B 
99
. Brierley et al. used a CRC cell line to demonstrate that knockdown of 
IR-A promoted formation and signaling through IGF1R homodimers, thus enhancing cell viability 
104
. 
Therefore, heterodimerization of IR and IGF1R may provide a mechanism to attenuate IGF1R receptor. 
 
Major downstream mediators 
 Insulin and IGF action can be mediated by receptor-induced activation of the insulin receptor 
substrates 1 and 2 (IRS-1 and IRS-2) or the Src homology 2 domain containing (Shc) proteins, which are 
immediately downstream of IGF1R and IR (Figure 1.5B). Tyrosine phosphorylation of IRS-1/2 can 
activate phosphoinositide 3-kinase (PI3K), which leads to phosphorylation of AKT and subsequent 
activation of molecules involved in glucose and lipid metabolism. Signaling through AKT can also favor 
cell differentiation 
96,105
 as well as cell growth and survival, for example, via inhibition of the pro-
apoptotic BAD 
106
. Shc proteins lead to activation of the RAS/MAPK pathway to promote proliferative 
and anti-apoptotic signals 
103,107
.   
IRS-1 knockout mice are about 50% smaller than their wild-type (WT) littermates and become 
mildly insulin resistant as they age 
108,109
. Loss of IRS-1 did not prevent insulin-induced phosphorylation 
of PI3K in liver and muscle and this residual insulin signaling was attributed to IRS-2 action 
108,109
. IRS-2 
knockout mice, on the other hand, are normal in size but develop peripheral insulin resistance and 
pancreatic β-cell dysfunction, consistent with a diabetic phenotype 110. Studies on fibroblasts isolated 
from IRS-1 knockout mice showed that IRS-1 deletion significantly decreased IGF1-induced proliferation 
and PI3K signaling 
111
 . Transfection of IRS-2 into these cells rescued activation of PI3K but had minimal 
effects on proliferation 
111
. In the mouse intestinal epithelium, IRS-1 was shown to be required for the 
anti-apoptotic actions of IGF1 and disruption of the IRS-1 gene dose-dependently increased apoptosis and 
reduced tumorigenesis 
112,113
. On the other hand, IRS-2 was shown to be induced by caudal-related 
homeobox protein 2 (CDX2) to promote differentiation in normal and tumor cells derived from human 
12 
colon 
114
. Together, these in vivo and in vitro data suggest that IRS-1 plays a larger role in mediating the 
mitogenic and anti-apoptotic effects of IGF1 while IRS-2 primarily mediates metabolic and 
differentiation signals. Overall, these studies lead to the concept that IR-B may signal preferentially 
through IRS-2 to mediate metabolic effects and differentiation, whereas IGF1R and IR-A may signal 
primarily via IRS-1 to promote cell proliferation, reduced apoptosis, and tumorigenesis (Figure 1.5 B).  
 
Impact of the insulin/IGF system on growth  
IGF1 is produced at highest levels in hepatocytes, but it is also expressed in several other tissues 
in the body, including the gut mesenchyme 
115,116
. IGF1 plays an important role in mediating the trophic 
actions of growth hormone (GH) to promote growth and development of various organs and is clinically 
used to treat children with growth failure due to genetic defects in the GH receptor 
117
. Mice deficient for 
IGF1R exhibit severe growth retardation and die shortly after birth 
118
. IGF2 is expressed in the fetus to 
regulate proliferation and apoptosis during embryonic development, while in human adults it is expressed 
mainly in the liver and exerts anti-apoptotic and proliferative actions through IR-A 
82,90
. In normal cells, 
the IGF2 gene is maternally imprinted and therefore the paternal allele is only expressed, and loss of 
imprinting has been found in many tumors 
82
.  
It is well established that IGF1 is a potent mediator of intestinal growth 
119
. IGF1 is produced in 
the mesenchyme and acts in a paracrine manner to induce mucosal growth and adaptation to surgical 
resection of the bowel 
116,120,121
. Local synthesis of IGF1 is stimulated by glucagon-like peptide 2 (GLP-
2), a gastrointestinal hormone that acts on GLP2 receptor in intestinal mesenchymal cells to stimulate 
IGF1 secretion
121
. GLP-2 exerts enterotrophic effects exclusively via IGF1 and a GLP-2 analog has been 
recently approved for treatment of short bowel syndrome 
122-125
. Mouse studies on the mechanisms of 
GLP-2 action to improve gut barrier function showed that signaling through IGF1R in intestinal epithelial 
cells was essential and this was associated with IGF1R-induced modulation of tight junction proteins 
126
. 
IGF1 produced in the liver and released into the circulation constitutes another source of IGF1 
that acts on the intestinal epithelium. In mice, circulating IGF1 increases intestinal mass and crypt cell 
13 
proliferation and survival during normal conditions, and infusion of IGF1 promotes growth of small 
intestinal epithelium during lack of luminal nutrients as occurs with total parenteral nutrition 
127,128
. 
Furthermore, exogenous IGF1 has been recently shown to enhance epithelial regeneration by expanding 
ISC following high-dose radiation 
129
. Studies performed in rats indicated that IGF1 treatment enhanced 
colonic mucosal growth and function and promoted healing after colonic anastomoses 
130,131
.  
Insulin is secreted into the bloodstream by the β-cells of the pancreatic islets after ingestion of a 
meal to regulate carbohydrate, lipid, or protein metabolism via IR 
132
. Mice deficient for IR are normal at 
birth but die of diabetic ketoacidosis 2-3 days after birth 
80,133
. In addition to the traditional actions of IR 
on metabolism, a role for IR in growth and development emerged from work by Dr. Efstratiadis’ group in 
1993 
118,134
. In these studies, the researchers observed that growth retardation was more dramatic in 
double mutant mice lacking IGF1 and IGF2 ligands or IGF2 and IGF1R than the respective single 
knockouts. Furthermore, in mice with intact IGF2 and null mutations in both IGF1 and IGF1R, residual 
growth was observed. These studies suggested the existence of some unknown receptor capable of 
mediating IGF2 signaling 
118,134
. In 1997, this unknown receptor was identified as IR and later found to be 
IR-A 
90,135
.   
Some studies have suggested that insulin can induce growth of the intestinal epithelium. In rat 
models of short bowel syndrome and mucosal damage, oral insulin treatment led to increases in overall 
small intestinal mass 
136,137
. These growth effects induced by insulin were associated with increased 
proliferation in the crypts and decreased apoptosis in the villi 
138
. It is important to note that despite these 
few studies, the impact of insulin in intestine has been under-investigated relative to studies of IGF1. 
Given the similarities in IGF1R and IR structure and the ability of IGFs and insulin to activate both 
receptors, the studies in this dissertation took the approach of genetic deletion of IGF1R or IR in mouse 
intestinal epithelium to better define their roles.  
IGF1R overexpression has been found in a number of tumors including colorectal 
adenocarcinomas and metastases 
139-141
. Furthermore, increased IGF1R signaling in tumor cells has been 
linked to resistance to chemotherapy and radiation treatments 
142,143
. IR-A is overexpressed relative to IR-
14 
B in tumors of the breast, thyroid, ovary, prostate, and colon 
90,107
. IR-A:IR-B mRNA ratio is increased in 
aggressive human colorectal cancer cell lines and in colon tumors of Apc
Min/+
 mice 
97
. This reflected 
primarily loss of IR-B rather than increased IR-A since total levels of IR mRNA were actually reduced in 
tumors relative to normal tissue 
97
. The ability of IR-A to mediate IGF1 and IGF2 action has presented a 
difficulty in the efficacy of anti-cancer drugs designed to block IGF1R. IGF1R inhibitors have been tested 
as anti-cancer therapies but in some tumors IR was able to confer resistance and support survival or 
growth despite IGF1R inhibition 
144-147
. This compensatory response of IR to IGF1R-targeted therapies 
led to development of dual IGF1R/IR inhibitors 
148-151
.  However, the concern with blocking IR is the 
potential for decreased insulin sensitivity and adverse metabolic consequences. Therefore, it is expected 
that therapies targeted to IGF1R and IR-A combined with insulin sensitizing agents would provide the 
most beneficial strategy 
151
. Defining risk factors for development of pre-cancerous adenomas and 
improved screening and prevention represent desirable goals to reduce CRC. One chapter of this 
dissertation undertook an epidemiologic study to assess whether levels of expressed IGF1R, IR, or IR-
A:IR-B mRNAs were associated with colorectal adenoma risk.     
 
Role of IGF binding proteins in regulating IGF action 
Normally, circulating IGFs are about 95% bound to IGF binding proteins (IGFBPs) 
152
. When IGFs are 
present in the unbound form, they become “free” to bind their receptors and initiate signaling. IGFBPs 
therefore limit “bioavailable” IGF for binding to IGF1R or IR. There are six IGFBPs that bind IGFs with 
high affinity. IGFBP-1 is synthesized by the liver and its production is known to be strongly suppressed 
by elevated plasma insulin. Human studies showed that IGFBP-1 is found at low levels in the plasma of 
obese, hyperinsulinemic individuals 
153,154
. Suppressed IGFBP-1 correlates with increased free IGF1 in 
serum, which was shown to be 50-70% higher in obese than in non-obese subjects 
154
. This increase in 
bioavailable IGF1 is associated with the adverse effects of obesity and hyperinsulinemia on cancer risk, 
including pre-cancerous colon adenomas 
155
. IGFBP-2 binds primarily to IGF2 and plays a role in 
regulating growth of a number of tissues during embryonic development 
156,157
. IGFBP-3 is the most 
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abundant in the circulation and is expressed in virtually all tissues in the body. Its major role is to 
modulate levels of free IGFs that signal through IGF1R to regulate cell proliferation, differentiation, and 
apoptosis 
158,159
. Although numerous studies investigated the roles of IGFBP-3 in cancer and metabolism, 
results have been inconsistent and whether IGFBP-3 promotes or protects against tumorigenesis and 
metabolic disorders remains unclear 
160,161
. In the intestine of rodents, IGFBP-3 mRNA is expressed 
mainly in the lamina propria and is decreased after small bowel resection, potentially facilitating the 
ability of IGF1 to promote mucosal growth 
162,163
. In human colon, IGFBP-3 protein expression is 
decreased in adenomas and adenocarcinomas, and low IGFBP-3 mRNA levels in normal mucosa have 
been associated with increased risk of colorectal adenomas 
164,165
. Consistent with this evidence, in vitro 
work has shown that IGFBP-3 is a transcriptional target of the tumor suppressor p53 and may promote 
apoptosis independent of IGF1 
166,167
. IGFBP-4 is expressed in several tissues including the intestine. A 
recent report using IGFBP4-KO mice concluded that circulating IGFBP-4 inhibits basal intestinal growth 
but is required to promote the trophic actions of GLP-2 on the intestinal epithelium 
168
. Another study 
using CRC cell lines overexpressing SOX9 and mice deficient for SOX9, an ISC marker 
169,170
, showed 
that IGFBP-4 mediates anti-proliferative actions of SOX9 on CRC cells and IEC 
171
. IGFBP-5 is also 
expressed in most tissues and, in the intestine, its expression is high in the muscularis layer and in 
mesenchymal cells of the lamina propria 
163
. Unlike IGFBP-3, local IGFBP-5 expression is thought to 
potentiate the trophic actions of IGF1 on the small intestine 
116,172
. In line with this concept, some 
evidence links IGFBP-5 to tumorigenesis in a number of cell types 
173
. IGFBP6 has a much higher 
binding affinity for IGF2 than IGF1 and may inhibit proliferative or anti-apoptotic actions of IGF2 
through IGF1R 
174,175
. A large body of data recently reviewed by Bach et al., 2013, indicate that IGFBP-6 
is a potential inhibitor of cancer, as its expression is reduced by β-catenin and increased by p53 in tumors 
175
. Additionally, studies have linked IGFBP-6 to decreased tumor growth and metastasis in a number of 
cancers, including colon cancer 
175
.  
 
16 
Obesity, hyperinsulinemia, and colorectal cancer 
 The World Health Organization (WHO) defines overweight and obesity as “abnormal or 
excessive fat accumulation that presents a risk to health”. Obesity is currently at epidemic levels, 
affecting 13% of the world population and 35% of the US population 
135,176
. Body mass index (BMI) is 
widely used to define obesity and is calculated using the formula (weight in kg)/(height in meters)^2. 
Normal or lean BMI ranges between 19.5 and 24.9 kg/m
2
, overweight corresponds to a BMI between 25.0 
and 29.9 kg/m
2
, and obese individuals have a BMI equal to or greater than 30.0 kg/m
2
.  Waist-to-hip ratio 
(WHR) is another measure of obesity that takes into account abdominal fat. WHR equal to or above 91 
and 99.5 cm in women and men, respectively, indicates abdominal or “central” obesity, which is one 
component of metabolic syndrome along with dyslipidemia, hypertension, and hyperglycemia 
177
. 
Insulin is produced by the β-cells of the islets of Langerhans in the pancreas and released into the 
circulation in response to a rise in blood glucose, aminoacids, and secretion of intestinal hormones after 
ingestion of a meal 
132
. Some of the effects of insulin include 1) glucose uptake in muscle and adipose, 2) 
decreased hepatic gluconeogenesis, 3) glycogen synthesis in muscle and liver, and 4) lipogenesis in liver 
and adipose tissue (Figure 1.6A) 
132,178
. To induce glucose uptake, insulin binding to IR recruits glucose 
transporters (GLUTs) to the cell membrane to facilitate glucose transport into the cell 
132
. Reduced blood 
glucose then signals to pancreatic β-cells to inhibit insulin production. Insulin resistance is a condition 
where peripheral tissues have a reduced ability to respond to circulating insulin at physiological levels 
and therefore glucose uptake is impaired (Figure 1.6B). The molecular basis of insulin resistance is not 
completely understood. Some proposed mechanisms include lipotoxicity, inflammation, hyperglycemia, 
mitochondrial dysfunction, and endoplasmic reticulum (ER) stress 
179
. All these mechanisms, which are 
reviewed in detail in Boucher et al., 2014, lead to phosphorylation of IR, IRS-1/2, or AKT at Ser/Thr 
residues that inhibit their kinase activity and therefore impair insulin signaling 
179
.  As a result of insulin 
resistance, blood glucose levels increase (hyperglycemia) and the pancreas therefore secretes more 
insulin to maintain normal glycemic levels and glucose metabolism 
180
. This compensatory response to 
insulin resistance leads to elevated plasma insulin, known as hyperinsulinemia (Figure 1.6B). Some 
17 
obese patients have hyperinsulinemia but whether this is a cause or a consequence of obesity remains 
unclear
 153,181
. In mouse models of diet induced obesity, hyperinsulinemia typically develops after 
increases in fat mass, indicating a role for obesity or functional consequences of obesity in driving insulin 
resistance and hyperinsulinemia 
67
. Insulin resistance and the inability to uptake glucose result in hepatic 
glycogen breakdown and conversion into glucose, which increases glucose output and further exacerbates 
hyperglycemia (Figure 1.6B) 
132,178
. Lipolysis occurs in adipose tissue, which leads to lipid accumulation 
in muscle 
178
. When increased insulin production is not sufficient to overcome insulin resistance and 
maintain normal glucose levels, fasting hyperglycemia and hyperinsulinemia occur, marking the onset of 
type 2 diabetes. At later stages in the progression of the disease, pancreatic β-cells become exhausted and 
dysfunctional, resulting in partial or complete insulin deficiency (Figure 1.6C) 
132
. Therefore, obesity, 
hyperinsulinemia, and type 2 diabetes are strongly linked and can lead to long-term complications such as 
metabolic syndrome, cardiovascular disease, and cancer.   
     
Evidence for the link between obesity and CRC 
 Obesity and type 2 diabetes have been widely associated with increased risk of multiple cancers, 
including CRC 
182-185
. Hyperinsulinemia and insulin resistance have been linked to increased risk of 
colorectal adenomas and cancer 
155,186-188
. Interestingly, those patients with elevated plasma insulin and 
adenomas had significanlty reduced apoptosis in their normal rectal mucosa, suggesting a potential 
mechanism by which insulin may promote formation of pre-cancerous lesions 
155,186
. In colorectal cancer 
patients treated with chemotherapy and EGFR inhibitors, elevated blood glucose and high BMI predicted 
accelerated disease progression 
189
. Additionally, rectal cancer patients with type 2 diabetes showed a lack 
of response to chemoradiotherapy 
190
. Obesity has been associated with increased recurrence and 
mortality following CRC treatment, as obese and morbidly obese patients with colon cancer appear to 
have increased recurrence and poorer survival after chemoradiotherapy 
191,192
. In contrast, some 
epidemiological studies suggested that weight loss decreases CRC risk 
193,194
. 
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 In the last years, there has been growing evidence supporting the concept that cancer risk 
associatd with type 2 diabetes may be influenced by anti-diabetic treatments. Human studies have shown 
a positive relationship between insulin therpies and cancer 
195,196
. Insulin analogs such as insulin glargine 
have also been associated with increased cancer risk, but results have been inconsistent 
196-198
. In contrast, 
use of biguanides such as metformin has been suggested to decrease cancer incidence in a number of 
organs via increased activation of adenosine monophosphate -activated protein kinase (AMPK) 
180,196,199,200
. AMPK is activated when energy levels in the cell are low and therefore stimulates catabolic 
pathways to produce energy 
200,201
. Thus, metformin-induced AMPK activation leads to increased glucose 
uptake and glycolysis and decreased hepatic gluconeogenesis, which attenuate hyperglycemia and 
hyperinsulinemia 
200,201
. Interestingly, AMPK activation is mediated by the tumor suppressor liver kinase 
B1 (LKB1), which is deficient in patients with Peutz-Jeghers syndrome, a hereditary polyposis disease 
that increases susceptibility to CRC 
202
. The signaling pathways downstream of AMPK that are involved 
in the anti-tumor effects of metformin are reviewed in Perncova and Korbonits, 2014 
200
. These 
mechanistic studies were performed mainly in cell lines and mice with the limitation that the doses of 
metformin used were much higher than those clinically used in humans.  
Together, elevated levels of plasma insulin associated with metabolic disease or anti-diabetic 
therapies represent a risk factor for colorectal carcinogenesis, poor CRC treatment efficacy, or increased 
moratlity after CRC treatment (Figure 1.7).       
 
Mediators and mechanisms of colorectal cancer risk during obesity 
 There are many proposed mechanisms of increased intestinal cancer risk associated with obesity 
and are summarized in Figure 1.8. The insulin/IGF1 pathway is likely to play a role in carcinogenesis 
given that obese individuals tend to have elevated plasma insulin and free IGF1 as well as decreased 
IGFBP1, which allows more free IGF1 in the circulation 
153,181
. Numerous human studies have found 
associations between IGF1 and IGF1R overexpression and CRC 
139-141,203,204
. IGF1 promotes activation of 
the oncogenic RAS/MAPK pathway, and constant exposure of tissues to IGF1 can therefore enhance 
19 
proliferation and tumor growth.  In vitro studies reported that inhibition of IRS-1 decreased proliferation 
of colorectal cancer cells 
205
. Furthermore, stabilization of β-catenin and phosphorylation of IRS-1 were 
induced by IGF1treatment, and Wnt/β-catenin signaling is an important transcriptional regulator of the 
IRS1 gene 
206,207
.  β-catenin stabilization results in nuclear translocation and activation of Wnt targets 
genes such as the stem cell marker Lgr5 
208
. In fact, a human study reported that LGR5 mRNA levels were 
increased in colorectal tumors relative to normal mucosa and this correlated with mRNA up-regulation of 
oncogenic cMYC 
209
. Furthermore, patients with high tumor LGR5 expression had decreased disease-free 
survival 
209
. Together, these studies suggest that mediators downstream of IGF1R/IR promote 
tumorigenesis but whether IGF1R or IR mediates these effects in the colon has not been directly tested. 
Hyperinsulinemia associated with obesity and diabetes is caused by hyperglycemia, as pancreatic 
β-cells attempt to lower blood glucose when glucose uptake is impaired. Hyperglycemia facilitates 
consumption of glucose by cancer cells, which obtain energy from glycolysis and lactate production in the 
cytosol rather than by oxidative phosphorylation in the mitochondria 
210,211
. This metabolic switch in 
cancer cells is called the Warburg effect and is thought to provide cancer cells with metabolites that favor 
cell proliferation 
211
. In line with this concept, hyperglycemia has been associated with increased cancer 
risk by positively influencing pathways that enhance proliferation, migration, and anti-apoptosis 
212
. 
  Adipokines are hormones that are produced mainly in adipose tissue and are also thought to 
contribute to the mechanisms of tumor growth during obesity 
210
. Leptin is secreted by adipocytes during 
the fed state and acts on the hypothalamus to suppress appetite, but it has also been implicated in tumor 
cell growth in the mouse colon 
213
. Proliferative effects of leptin on colon cancer cells appeared to be 
mediated by the signal transducer and activator of transcription 3 (STAT3) 
213
. In humans, obesity is 
linked to leptin resistance at the level of the leptin receptor, but epidemiological studies linking serum 
leptin concentrations to cancer risk remain inconclusive 
210
. On the other hand, adiponectin, which is 
another hormone released by adipose tissue, is found at low levels in the plasma of obese and diabetic 
patients 
214
. In the mouse colon, adiponectin deficiency led to increased polyp number and colon cell 
proliferation only during diet-induced obesity, and administration of adiponectin inhibited colon tumor 
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growth in obese animals 
215,216
. In vitro experiments in a mouse colon adenocarcinoma cell line showed 
that adiponectin exerts anti-proliferative actions via decreased STAT3 phosphorylation 
217
.  
 As mentioned earlier, chronic inflammation associated with obesity has been widely implicated in 
CRC development. Elevated plasma concentrations of the pro-inflammatory cytokine IL-6 have been 
found in patients with colorectal adenomas and cancer and were associated with high BMI and abdominal 
obesity 
218,219
. Moreover, number and size of tumors were reduced in AOM-DSS treated mice lacking IL-
6 
220
. In Apc
Min/+
 mice, HFD feeding led to increased expression of markers of inflammation such as IL-
12, IL-6 and TNF-α in adipose and intestinal tumor tissue 221. In vitro studies in CRC cells lines have 
shown that IL-6 and TNF-α act via STAT3 to promote expression of TNF receptor 2 (TNFR2) and 
proliferation 
222
. In summary, a large body evidence exists to support the contributions of insulin/IGF1 
signaling, hyperglycemia, adipokines, and inflammation to the mechanisms underlying increased CRC 
risk during obesity and insulin resistance (Figure 1.8).   
 
Overview of apoptosis 
Intrinsic apoptosis pathway 
 Apoptosis is a programmed cell death that the body uses to eliminate unwanted cells and is 
essential during tissue development, regeneration, and maintenance. In adult tissues, apoptosis generally 
occurs in order to remove cells with damaged and unrepaired DNA, which may otherwise accumulate 
mutations and acquire cancerous potential.  Stimuli that trigger apoptosis include growth factor 
withdrawal and DNA damage caused by toxins, infection, or ionizing radiation 
223
. The balance between 
apoptosis and survival is critical to tissue homeostasis, as excessive apoptosis can lead to degenerative 
diseases and insufficient apoptosis can lead to the development of cancer 
223
.  
 Depending upon whether the pro-apoptotic signals are intracellular or extracellular, apoptosis 
occurs via the intrinsic or extrinsic pathway, respectively, which are reviewed in detail by Ashkenazi, 
2008 
223
. Both forms of apoptosis involve cysteinyl aspartate-specific proteases called caspases, which 
21 
are activated by proteolytic cleavage in a process known as the caspase cascade, leading to DNA 
fragmentation in the nucleus and execution of apoptosis 
224
.  
The intrinsic pathway, also known as the mitochondrial pathway, is initiated by intracellular 
events such as DNA damage and is illustrated in Figure 1.10. Radiation, chemotherapy, UV light, and 
other types of cellular stresses cause double-stranded breaks (DSB) in DNA. DSBs are recognized by the 
kinase ataxia telangiectasia mutated (ATM) 
225
, which initiates the DNA damage response by activating 
p53 
226,227
, a tumor suppressor that is critical to mediating death and survival signals. As a consequence, 
p53 translocates to the nucleus to initiate transcription of genes encoding pro-apoptotic proteins such as 
NOXA, PUMA, and PERP, as well as genes encoding mediators of cell cycle arrest such as p21 
228
. Pro-
apoptotic targets of p53 inhibit anti-apoptotic BCL-2 and BCL-XL and activate pro-apoptotic BAX and 
BAK. BAX and BAK directly promote permeabilization of the mitochondrial membrane which causes the 
release of Cytochrome C and Smac/DIABLO from the mitochondrion into the cytosol 
223
. Cytochrome C 
binds to apoptotic protease activating factor 1 (APAF-1) to recruit the initiator caspase-9 into the 
apoptosome complex. The apoptosome stimulates cleavage and activation of caspase-9, which in turn 
cleaves and activates effector caspases such as caspase-3. Smac/DIABLO further contributes to the 
caspase cascade by inactivating the inhibitor of apoptosis proteins (IAPs) 
223
. Cleaved caspase-3 is a 
critical mediator of chromatin condensation, DNA fragmentation, and membrane blebbing, which result 
in the formation of apoptotic bodies that are engulfed by phagocytosis 
229
.       
The extrinsic pathway is triggered by cytotoxic immune cells which release pro-apoptotic ligands 
that belong to the TNF superfamily such as TNF-related apoptosis-inducing ligand (TRAIL) and Fas 
ligand (FasL) 
223
. TRAIL binds to death receptors 4 or 5 (DR4/5) and FasL signals through Fas receptor 
(FasR), which are located at the surface of the target cell. This promotes activation of initiator caspases 8 
and 10 and subsequent activation of downstream effector caspases (Figure 1.9) 
223
. The current studies 
have used cleaved caspase-3 as a major readout for radiation/genetic damage-induced apoptosis. 
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Apoptosis in the colonic crypts 
 Cell death in the colonic epithelium occurs at two main sites: 1) in the bottom half of the crypts 
by apoptosis in order to remove genetically damaged stem or progenitor cells that could initiate neoplastic 
lesions and 2) at the luminal surface where differentiated cells are detached and shed into the lumen by a 
process known as anoikis, which is related to apoptosis and part of normal intestinal epithelial renewal. 
Levels of spontaneous apoptosis in the intestinal crypts are low and much lower in the colon than in the 
small intestine 
230
. The particularly low rates of apoptosis in the colon are attributed to decreased basal 
expression of p53 and increased BCL-2, and this may contribute to the higher incidence of tumors in the 
colon than in the small intestine 
231,232
.   Another difference between the two bowel regions is that while in 
the small intestine basal and induced apoptosis occurs primarily within the stem cell zone at the crypt 
base, in the colon apoptotic cells are present throughout the length of the crypt 
230,233
.  
During homeostasis, the major mediator of apoptosis in colonic crypts is BCL-2, as Bcl2 
knockout mice exhibited increased levels of apoptosis relative to WT mice 
232
. However, p53 and BAX 
appear to have little role in spontaneous apoptosis since mice deficient for these proteins showed similar 
apoptosis levels to those in WT animals in the basal state 
234
. To better study the apoptotic response in the 
intestinal crypts, models of DNA damage induced by 1-6 Gy radiation have been widely used 
113,233,235,236
. 
Studies in rodents showed that following radiation, there two large waves of apoptosis 
237
. The first one 
occurs 3-6 hours after radiation and requires p53, as mice lacking p53 showed significantly reduced 
apoptosis at 3-4.5 hours post-radiation 
231,238
. The second wave of apoptosis, also known as “mitotic 
catastrophe” 231, occurs 24 hours later and is thought to result from genetically damaged cells with 
unrepaired DNA that re-enter the cell cycle and attempt to undergo mitosis but die due to chromosomal 
aberrations. This later wave of apoptosis has been shown to be p53-independent 
231
. BCL-2 was also 
reported to play an important role in regulating colon crypt cell apoptosis within the initial hours after 
DNA damage, whereas BAX was shown to have little impact on p53-dependent apoptosis 
234
. Whether 
obesity, IGF1R, or IR affects apoptosis of genetically damaged colon epithelial cells has not been 
23 
explored and could provide mechanistic insight into early events that promote survival of aberrant cells 
that could initiate tumors.   
 
Research hypotheses     
Distinguishing the specific functions of the IGF1R versus the IR in situations of elevated insulin 
has been a long standing challenge due to the high degree of crosstalk between both receptors. 
Understanding the individual contributions of each receptor to CRC risk and initiation is critical to 
developing and improving strategies for CRC prevention, diagnosis, and treatment, especially in the 
current epidemic of obesity and insulin resistance. This work has used human biopsies and genetic mouse 
models to investigate the specific roles of IGF1R and IR in colon adenoma risk, tumorigenesis, and 
epithelial cell survival after DNA damage during hyperinsulinemia, obesity, or inflammation. The 
following hypotheses have been tested (Figure 1.10): 
1. Increased IGF1R relative to IR mRNA or increased IR-A:IR-B ratio in normal mucosa 
predicts colorectal adenomas in humans, and this is associated with elevated plasma insulin. 
2. IGF1R is the main mediator of colorectal tumorigenesis while IR exerts protective effects by 
attenuating IGF1R signaling. Therefore, IR loss favors formation of tumors. 
3. Diet-induced obesity and hyperinsulinemia lead to decreased apoptosis of genetically 
damaged colon epithelial cells. 
4. IGF1R is a critical mediator of the anti-apoptotic actions of obesity and hyperinsulinemia. 
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Figures  
 
 
Figure 1.1: Tissue layers and crypt cell types in the mammalian large intestine. 
(A) The colon epithelium consists of three main layers that can be visualized by histology. The mucosa 
consists of (i) a single layer of columnar epithelial cells that forms the crypts, (ii) stromal connective 
tissue surrounding the crypts (lamina propria) that contains immune cells important for defense, and (iii) 
an underlying layer of smooth muscle cells (muscularis mucosa). The submucosa is a thin layer of 
connective tissue containing small blood vessels. The muscle layer, or muscularis propria, is composed 
of circular and longitudinal smooth muscle tissues. Although not visible in this figure, two neural plexi 
exist: the submucosal plexus and the myenteric plexus between the two muscle layers of the muscularis 
propria. (B) Histological image (left) and schematic representation (right) of the colonic crypt. Stem cells 
residing at the base of the crypts give rise to progenitor cells which actively divide and migrate upwards 
as they differentiate into colonocytes, goblet cells, or enteroendocrine cells. Mesenchymal myofibroblasts 
surround the crypts and may provide Wnt ligands to regulate proliferation. Indian hedgehog (Ihh) 
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produced by differentiated cells stimulate myofibroblasts to secrete Bmp to attenuate proliferation and 
promote differentiation. Notch and EGF secreted by epithelial cells also help maintain stem cell function. 
(References: van Dop et al., 2009; Sato et al., 2011, Krausova et al., 2014; Rothenberg et al., 2012. Crypt 
diagram modified from Medema and Vermeulen, 2011).    
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Figure 1.2: Progression from normal colon epithelium to adenocarcinoma. 
A loss of function mutation in the APC gene and microsatellite instability can lead to the formation of 
aberrant crypt foci (ACF). Progression to adenoma can involve mutations that lead to overexpression of 
KRAS and loss of SMAD2/4 as well as altered epigenetic modifications in DNA repair genes. Mutations 
on the gene encoding the tumor suppressor p53 cause progression to malignancy and development of 
invasive adenocarcinoma. (Diagram modified from Davies et al., 2005, and Markowitz and Bertagnolli, 
2009).  
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Figure 1.3: Chemically-induced models of colorectal cancer (CRC). 
(A) The AOM model of CRC consists of 4-6 weekly injections with AOM with not further treatment. 
Animals tend to develop colorectal tumors approximately 20 weeks after the last AOM injection. (B) The 
AOM-DSS model of CRC involves a single intraperitoneal injection of AOM followed by three DSS 
treatments for 5-7 days. A recovery period consisting of water drinking occurs between each DSS cycle.  
This model allows numerous colorectal tumors to develop by 2-2.5 months as a result of chronic 
inflammation and mucosal damage induced by multiple exposures to DSS. 
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Figure 1.4: The insulin and IGF1 receptors. 
(A) The insulin-like growth factor 1 receptor (IGF1R) and the insulin receptor (IR) belong to the receptor 
tyrosine kinase family. They are composed of two α-subunits (ligand binding domain) and two β-subunits 
(tyrosine kinase domain). Although they bind preferentially to their own ligand, both receptors can be 
activated by IGF1, IGF2, or insulin when present at high levels in the circulation. (B) Traditional views 
associate IGF1R with growth, anti-apoptotic, and tumorigenic actions of IGFs. IR is expressed as two 
isoforms resulting from alternative pre-mRNA splicing. IR-A lacks exon 11, binds strongly to insulin and 
IGF2, and is overexpressed in fetal and cancer cells. IR-B includes exon 11, binds primarily to insulin, 
mediates glucose and lipid metabolism in insulin-target tissues, and may play a role in cell differentiation.  
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Figure 1.5: Ligand binding affinities and proposed downstream signaling pathways of IGF1R, IR-
A, and IR-B. 
(A) IGF1R and both hybrid IGF1R:IR-A (HR-A) and IGF1R:IR-B (HR-B) receptors bind to the IGFs 
with higher affinity than to insulin. Both IR isoforms bind preferentially to insulin, but IR-A has a high 
affinity for IGFs and IR-B does not. In the diagram, closer proximity of a ligand to a receptor indicates 
increased binding affinity. (B) Growing evidence suggests that IGF1R and IR-A share a common 
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signaling pathway in which Shc and IRS-1 proteins are phosphorylated following ligand binding. Shc 
activates the MAPK pathway via phosphorylation of RAS and ERK, while IRS-1 activates PI3K/AKT 
signaling, leading to cell growth, survival, and cancer. IR-B likely signals through IRS-2 to activate 
PI3K/AKT and mediate the metabolic effects of insulin in insulin-target tissues or promote cell 
differentiation. IRS-2 actions on differentiation are positively regulated by CDX2, as suggested by 
Modica et al., 2009. (Adapted and modified from Frasca et al., 2008, and Belfiore and Malaguarnera, 
2011).          
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Figure 1.6: Glucose metabolism during healthy conditions and insulin resistance. 
(A) After a carbohydrate-rich meal, glucose is sensed by the β-cells of the pancreatic islets which secrete 
insulin into the circulation to decrease hepatic gluconeogenesis and promote glucose uptake in skeletal 
muscle and adipose, glycogen synthesis in liver and muscle, and lipogenesis in liver and adipose tissue. 
As a result, blood glucose levels decline and the pancreas ceases to secrete insulin. (B) During insulin 
resistance, tissues are insensitive to circulating insulin. This causes hyperglycemia, which in turn causes 
the pancreas to secrete more insulin, leading to hyperinsulinemia. The inability of tissues to uptake 
glucose causes the liver to increase glycogen breakdown, gluconeogenesis and glucose secretion, which 
further increases blood glucose levels. Additionally, lipogenesis is increased in adipose tissue, leading to 
lipid accumulation in muscle. (C) When the pancreatic β-cells can no longer secrete enough insulin to 
maintain homeostatic glucose levels, they become dysfunctional and die, resulting in insulin deficiency 
and type 2 diabetes. (References: Samuel and Shulman 2012 and Lippincotts' Illustrated Reviews, 
Biochemistry. 3rd ed).  
    
32 
 
 
 
 
Figure 1.7: Adverse consequences of hyperinsulinemia on the colon. 
Hyperinsulinemia caused by obesity, insulin resistance, type 2 diabetes, and/or insulin therapies can have 
implications in increased risk of colorectal adenomas or cancer, decreased response to treatments, and 
increased recurrence and mortality following treatment. (References: Keku et al., 2005; Vidal et al., 2012; 
Giovannucci, 2007; Tsai  and Giovannucci, 2012; Pantano et al., 2013; Caudle et al., 2008; Dignam et al., 
2006; Sinicrope et al., 2013).    
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Figure 1.8: Suggested mechanisms of obesity-induced colorectal cancer risk. 
Excess adiposity during obesity leads to enhanced production of inflammatory cytokines and leptin, 
which induce STAT3 activation to increase proliferation and reduce apoptosis in the colonic mucosa. 
Production of adiponectin, which normally inhibits STAT3, is reduced during obesity. Hyperinsulinemia 
decreases hepatic production of IGFBP1, allowing more free IGF1 in the circulation. IGF1, as well as 
insulin, can activate IGF1R or IR in colon epithelial cells to exert proliferative and anti-apoptotic actions. 
Finally, hyperglycemia associated with obesity or hyperinsulinemia promotes the switch from aerobic to 
anaerobic glycolysis, known as the “Warburg effect”, which favors production of metabolites and 
nutrients that are utilized by tumor cells. (See section “Mediators and mechanisms of colorectal cancer 
risk during obesity” of this dissertation for references).        
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Figure 1.9: Apoptosis pathways. 
Intrinsic pathway: DNA damage caused by cellular stressors such as radiation is sensed by p53, which 
translocates to the nucleus to induce transcription of apoptotic mediators PUMA, NOXA, and PERP. 
These mediators inhibit anti-apoptotic BCL-2 and BCL-XL, thereby allowing activation of pro-apoptotic 
BAX and BAK, which cause permeabilization of the mitochondrial membrane and efflux of Cytochrome 
C and Smac/DIABLO. Cytochrome C promotes formation of the apoptosome where the apoptotic 
protease activating factor 1 (APAF-1) cleaves and activates caspase-9, which in turn cleaves and activates 
caspase-3. Smac/DIABLO released by the mitochondrion negatively regulates the inhibitor of apoptosis 
protein (IAP) complex, further allowing caspase activation. Extrinsic pathway: Extracellular factors such 
as TNF-related apoptosis-inducing ligand (TRAIL) and Fas ligand (FasL) are secreted from cytotoxic 
immune cells. TRAIL binds to death receptor 4 or 5 (DR4/5) and FasL to Fas receptor (FasR) in order to 
activate caspases 8 and 10, which subsequently activate caspase-3. Cleaved caspase-3 moves to the 
nucleus to fragment DNA and execute apoptosis, which ultimately results in the formation of apoptotic 
bodies that are phagocytized by macrophages. (References: Attardi and DePinho, 2004, diagram modified 
from Ashkenazi, 2008).    
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Figure 1.10: Research aims and hypotheses. 
This dissertation tested the central hypothesis that IGF1R is an essential mediator of the adverse effects of 
obesity, hyperinsulinemia, and inflammation that favor risk of CRC. Aim 1 in Chapter 2 used normal 
rectal biopsies from human patients to examine whether increased IGF1R mRNA, decreased IR mRNA, 
or elevated IR-A:IR-B ratio predicted colorectal adenoma risk, especially during obesity or 
hyperinsulinemia. Aim 2 in Chapter 3 used a genetic mouse model of IR deletion in the intestinal 
epithelium to test the hypothesis that IR protects against inflammation-induced CRC and its loss leads to 
increased tumorigenesis by enhancing IGF1R action. Finally, Aim 3 in Chapter 4 evaluated the roles of 
IGF1R and IR in apoptosis of colon epithelial cells that underwent DNA damage, which is considered an 
early step in the initiation of neoplastic lesions. This final aim tested the hypothesis that obesity or 
hyperinsulinemia decreases apoptosis of genetically damaged colon epithelial cells and IGF1R is the main 
mediator of these anti-apoptotic effects in mice.       
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CHAPTER 2: REDUCED INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR AND ALTERED 
INSULIN RECEPTOR ISOFORM mRNAs IN NORMAL MUCOSA PREDICT COLORECTAL 
ADENOMA RISK
1
 
 
Introduction 
 Despite increased colonoscopy-based screening and improved treatment strategies 
239
, colorectal 
cancer (CRC) remains the second leading cause of cancer-related deaths in the United States 
3
. Obesity, 
insulin resistance and type 2 diabetes are considered risk factors for CRC 
187,240,241
. Previous work by our 
group has linked elevated plasma insulin and low apoptosis in normal rectal mucosa to increased 
adenoma risk 
155,165,186
. Elevated plasma insulin (hyperinsulinemia) can increase levels of free insulin-like 
growth factor 1 (IGF1) in the circulation by inhibiting the production of IGF binding protein 1 (IGFBP1) 
153,242
. In recent years, there has been increasing interest in targeting the insulin/IGF pathway for cancer 
treatment, as a large body of evidence links insulin/IGF1-mediated activation of insulin receptor (IR) or 
IGF1 receptor (IGF1R) to cancer of multiple organs 
86,107,112,180,243,244
. Furthermore, a number of studies 
have shown that IGF1R confers resistance to radiation therapy and chemotherapy 
245,246
, and clinical 
evidence links IGF1R over-expression to colorectal tumor formation and progression 
140,247
. Although 
IGF1R inhibitors showed a potential to reduce tumor growth 
144,145
, recent reports suggested that IR may 
permit tumors to resist IGF1R inhibition, which led to the development of dual IGF1R/IR inhibitors
146-149
.  
Considerable evidence has highlighted the potential significance of different IR isoforms in 
growth and cancer 
90,92,107
. The IR gene yields two distinct IR isoforms due to alternate pre-mRNA 
splicing. IR-B is encoded by an mRNA that includes exon 11 and is the primary mediator of the 
metabolic actions of insulin 
86,96
. IR-A is encoded by an mRNA that lacks exon 11, plays a role in fetal
                                                          
1
 This chapter was published in the journal Cancer Epidemiology, Biomarkers & Prevention. The citation for this article is 
as follows: M.A. Santoro, S.F. Andres, J.A Galanko, R.S. Sandler, T.O. Keku, and P.K. Lund. Reduced Insulin-like 
Growth Factor I Receptor and Altered Insulin Receptor Isoform mRNAs in Normal Mucosa Predict Colorectal Adenoma 
Risk. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2093-100. 
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growth and may mediate proliferative or anti-apoptotic actions of insulin or the IGFs 
90,92
. Evidence that 
IR-A may be the predominant IR isoform in tumors or tumor cells 
86,90-92,107
, including colon tumors 
97,104
, 
has increased attention on this isoform as a possible mediator of cancer development or growth. However, 
the finding that IR-A knockdown increased viability of a colon cancer cell line via enhanced IGF1R 
activation indicates that when IGF1R signaling is intact, IR may limit IGF1R signaling 
104
. Thus, the roles 
of IGF1R vs. IR in promoting colorectal tumorigenesis are not defined.   
Little attention has been given to IGF1R and IR mRNA expression patterns during pre-neoplastic 
stages of malignancy, including whether IGF1R or IR levels in normal colorectal tissue differ between 
patients with adenomas and patients without adenomas. We hypothesized that elevated mRNA levels of 
IGF1R vs. IR or elevated IR-A:IR-B ratio in normal mucosa are associated with increased colorectal 
adenoma risk, elevated plasma insulin, and overweight/obese body mass index (BMI). To address this 
hypothesis, biopsies from normal rectal mucosa were obtained from adenoma or adenoma-free patients 
undergoing routine colonoscopy. Levels of mRNAs encoding IGF1R, IR and IR isoforms were quantified 
and the relationship between their expression, adenoma status, BMI and plasma insulin was evaluated.  
 
Materials and methods 
Participants  
Participants were randomly selected from eligible subjects enrolled in the Diet and Health Study 
V (DHS V) who provided written informed consent and underwent routine colonoscopy at the University 
of North Carolina Hospitals, Chapel Hill, NC. The DHS V cohort has been described in previous studies 
62,248-250
. For the present study, a subset of 100 cases and 98 controls were selected so that the two groups 
were matched based on age, gender and BMI. Patients were excluded from the study if they had cancer, 
colitis, 100 or more polyps (polyposis), prior resection of the colon, or history of colorectal adenomas. 
Colonoscopy was performed by certified gastroenterologists and all polyps were removed for pathological 
examination and were not available for research purposes. Adenomas were confirmed and defined 
according to standard pathological criteria. Subjects with one or more adenomas were classified as 
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“cases” and those without adenomas as “controls”. The study was approved by the School of Medicine 
Institutional Review Board at the University of North Carolina, Chapel Hill. 
 
Data collection 
Methods for data collection were previously described 
62,248-250
. Briefly, participants fasted 
overnight and body weight, height, and waist and hip circumference were measured at the time of 
colonoscopy. Within 3 months after colonoscopy, patients were interviewed by telephone to provide 
information about their lifestyle, diet and demographics. BMI between 18.5-24.9 kg/m
2
 (lean) was 
defined as “normal” and BMI equal to or higher than 25 kg/m2 (overweight/obese) was defined as 
“Ovt/Ob”. 
 
Biological specimens and laboratory assays 
Prior to the endoscopic procedure, normal mucosal pinch biopsies were obtained 8-12 cm from 
the anal verge using standard disposable, fenestrated forceps. Sampling site was the same in all patients. 
Two biopsies were pooled for RNA extraction and immediately flash frozen in liquid nitrogen and later 
transferred to -80ºC. Another biopsy was fixed in 10% buffered formalin for histology and evaluation of 
apoptosis. Blood was collected via an intravenous catheter prior to administration of medication. Plasma 
was separated and insulin levels assayed for 95 controls and 79 cases by ELISA (Diagnostic Systems 
Laboratory, Webster, TX) as previously described 
186
. Plasma insulin levels below or above the median 
were defined as “low” or “high”, respectively.  
 
Assays for apoptosis  
Formalin fixed rectal biopsies were embedded in paraffin. Apoptosis was scored by terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) using ApopTag Peroxidase In Situ 
Apoptosis Detection Kit (Millipore, Billerica, MA). This technology detects apoptotic cells by 
incorporating digoxigenin-conjugated nucleotides to the 3’OH termini of DNA fragments utilizing 
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terminal deoxynucleotidyl transferase (TdT). Briefly, samples were deparaffinized in 100%, 95% and 
70% ethanol, digested in proteinase K and blocked in 2% hydrogen peroxide. TdT reaction was 
performed for 1.5 hours at 37ºC. Anti-digoxigenin conjugate was applied to the slides for 30 minutes, 
followed by a DAB (3, 3'-Diaminobenzidine) reaction for 1 minute. Samples were counterstained with 
hematoxylin and dehydrated with 95% and 100% ethanol and xylene. Slides were coverslipped using 
Eukitt mounting medium (Sigma-Aldrich, St. Louis, MO) and visualized with a bright-field microscope. 
Open crypts with good orientation were selected for scoring. The mean number of TdT-labeled apoptotic 
cells per crypt was calculated for each patient sample by investigators blinded to adenoma status. Due to 
the low number of samples available for apoptosis scoring (21 controls and 68 cases), it was only possible 
to compare apoptosis in cases versus controls without further stratification.  
 
RNA Extraction, Reverse Transcription (RT), and PCR  
RNA was extracted from biopsies using RNeasy Kit (Qiaen, Valencia, CA) and reverse 
transcribed with High Capacity cDNA Reverse Transcription Kit, including RNase inhibitor (Applied 
Biosystems, Carlsbad, CA) according to manufacturer’s protocol. Quantitative real-time polymerase 
chain reaction (qRT-PCR) used the 7500 Real-Time PCR System (Applied Biosystems, Carlsbad, CA) to 
quantify IGF1R and IR mRNA levels. Hydroxymethylbilane synthase (HMBS), which we have found to 
be invariant across rectal biopsy mRNAs, was used as the housekeeping gene for normalization. The 
following TaqMan primer/probes (Applied Biosystems, Carlsbad, CA) were used: Hs00951562_m1 
(IGF1R), Hs00961550_m1 (IR), and Hs00609297_m1 (HMBS). Pooled cDNA from colorectal cancer cell 
lines (Caco-2, SW480, Colo205) was run in all assays as a positive, internal control to account for inter-
run variability. Samples were run in duplicate and water was run as a negative control. Reaction cycles 
consisted of initial denaturation at 95°C for 5 minutes, 45 cycles of 95°C denaturation for 15 seconds and 
60°C annealing for 45 seconds. Data were analyzed using the Applied Biosystems 7500 software v2.0.1 
and expression levels were calculated using the standard curve method. These values were then 
normalized to HMBS and to the internal control.  
    
40 
 
IR isoforms A and B were assessed by traditional, semi-quantitative PCR using 150 ng of cDNA 
template. Forward primer 5’-GAATGCTGCTCCTGTCCAAA -3’ and reverse primer 5’- 
TCGTGGGCACGCTGGTCGAG -3’ (Integrated DNA Technologies, Coralville, IA) were designed to 
flank exon 11, resulting in 250 bp (IR-B) and 214 bp (IR-A) amplified fragments. PCR protocol was 
modified from Brierley et al.
104
 and consisted of initial denaturation at 92°C for 5 minutes followed by 40 
cycles of 92°C denaturation for 30 seconds, 60°C annealing for 30 seconds and 72°C extension step for 
30 seconds. Water and the internal control cDNA mentioned above were included in every assay. PCR 
products were run and visualized in a 2.5% agarose gel and band intensities were measured using Image J 
software (National Institutes of Health). Ratios of IR-A to IR-B were calculated for each patient sample 
and normalized to the internal control. All PCR assays were performed by an investigator blinded to case-
control and BMI status, and samples were randomly organized by another investigator so that all the 
groups were represented in each assay run.  
 
Statistical analysis  
Means and standard errors were computed for continuous variables. Differences in continuous or 
categorical variables between adenoma cases and adenoma-free controls were compared by Student’s t-
test or Chi-square test, respectively. BMI was divided into “normal” and “Ovt/Ob” (overweight/obese) 
and plasma insulin levels into “low” (below the median) and “high” (above the median) subgroups as 
described above. For each receptor mRNA, the levels in controls were used to generate quartiles, and the 
lowest quartile was considered as reference. Logistic regression models were used to compute odds ratios 
(ORs) and 95% confidence intervals (CIs) to examine the association between mRNA quartiles 
(predictors) and adenoma status (response). We also calculated P-values for interactions between mRNA 
variables and BMI/insulin subgroups in a model testing for an association with case status. The 
relationship between plasma insulin and receptor mRNA levels was evaluated by Spearman’s correlation 
coefficient. P-values less than 0.05 were considered statistically significant. All analyses were performed 
using SAS Version 9.3 (SAS Institute, Cary, NC).  
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Results 
Patient samples in this study were selected so that cases and controls were matched on age, sex 
and BMI. Subject characteristics are summarized in Table 2.1. Race was not associated with control or 
case status, and no differences in WHR, reported calorie intake or reported physical activity were 
observed between cases and controls. Consistent with previous studies from our group 
155,165
, adenoma 
cases showed lower apoptosis (P = 0.008) and a trend towards increased plasma insulin (P = 0.055) 
relative to adenoma-free controls.  
IGF1R and IR mRNA levels in normal rectal mucosa were quantified by qRT-PCR. IR-A and IR-
B mRNAs were assessed by standard PCR, where amplification of both isoforms by identical primers 
allowed us to calculate the ratio of IR-A:IR-B amplicon in each patient sample. We first compared mean 
mRNA levels between controls and cases overall and after stratifying for BMI and plasma insulin (Table 
2.2). Overall, cases had significantly lower IGF1R mRNA levels (P = 0.0003) than controls. This 
reduction in IGF1R mRNA was statistically significant in both normal (P = 0.02) and Ovt/Ob (P = 0.01) 
BMI subgroups and in subjects in the lower half of plasma insulin (P = 0.007). Since cases had slightly 
higher plasma insulin levels than controls, and elevated insulin can down-regulate IGF1R as a 
consequence of increased free IGF1 in the circulation 
251,252
, we asked if the lower IGF1R mRNA 
observed in cases could be associated with higher plasma insulin. Therefore, we examined IGF1R mRNA 
levels in controls versus cases after adjusting for plasma insulin. This analysis showed that even after 
controlling for insulin, cases still had lower IGF1R than controls (P = 0.005). Total IR mRNA levels did 
not differ between cases and controls in any subgroup categorized for BMI or plasma insulin. IR-A:IR-B 
ratio was 1.96 ± 0.04 in controls and 1.96 ± 0.03 in cases, demonstrating approximately 2 fold higher IR-
A mRNA expression in human rectum compared with IR-B, but no significant difference in cases and 
controls as a whole or when stratified for BMI (Table 2.2). Interestingly, among patients with high plasma 
insulin, adenoma cases had small but significant increases in IR-A:IR-B ratios relative to controls (P = 
0.006), which qualitatively reflected reduced IR-B mRNA (Figure 2.1).  
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To further evaluate the potential relationship between mRNA levels and colorectal adenoma risk, 
we studied the association between quartiles of IGF1R, IR and IR-A:IR-B mRNA expression and the 
odds of being a case, with the lowest quartile set as the reference (Table 2.3). Subjects in the highest two 
quartiles for IGF1R mRNA were significantly less likely to be cases. There were no significant 
associations between IR mRNA, IR-A:IR-B ratio and case status. To explore the association between 
receptor mRNA expression and adenoma risk in each subgroup, we used a logistic regression model to 
test for interactions between mRNA levels and BMI or plasma insulin status (Table 2.4). We found no 
interactions between BMI or plasma insulin and either IGF1R or IR mRNA levels. We did, however, 
observe a significant interaction between plasma insulin and IR-A:IR-B ratio (P = 0.005). With increasing 
IR-A:IR-B mRNA ratios, patients with high plasma insulin were more likely to have adenomas than were 
patients with low plasma insulin (Figure 2.2).  
We next compared mRNA expression between subgroups in controls and cases separately. We 
found that in the control group, subjects with high plasma insulin had reduced mean IGF1R, IR and IR-
A:IR-B mRNA levels (P = 0.048, P = 0.02, P = 0.01, respectively) relative to subjects with low plasma 
insulin. This association was not found in cases. Qualitative evaluation of the IR isoforms suggested that 
the reduced IR-A:IR-B ratio observed in controls with high insulin reflected higher IR-B (Figure 2.1). To 
further examine the possible effect of elevated insulin on gene expression, we calculated the correlation 
coefficients between plasma insulin and IGF1R, IR and IR-A:IR-B mRNA levels (Table 2.5). We indeed 
found significant negative correlations between plasma insulin and all three mRNA variables in controls, 
while in cases this relationship was significant only for IGF1R mRNA. In fact, in cases there was a non-
significant trend for a positive correlation between IR-A:IR-B ratio and plasma insulin (P = 0.06).       
 
Discussion 
This case-control study provides novel evidence that, compared to adenoma-free controls, rectal 
biopsies from grossly normal mucosa of patients with adenomas are likely to have i) significantly lower 
levels of IGF1R mRNA, ii) unaltered IR mRNA, and iii) higher ratios of IR-A:IR-B isoforms in those 
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individuals with elevated plasma insulin. Consistent with our previous findings in three different patient 
groups 
155,165,186
, the presence of adenomas was associated with reduced apoptosis in normal appearing 
rectal mucosa and increased plasma insulin, although the latter was borderline significant in this smaller 
study population. 
Identifying molecular biomarkers that predict early pre-cancerous lesions could significantly 
improve our understanding of factors that promote CRC risk, which could eventually contribute to better 
CRC prevention or screening. This study aimed to establish whether elevated mRNA expression of 
IGF1R, IR or relative expression of isoforms IR-A and IR-B in normal rectal mucosa predicts adenomas 
and whether this is influenced by BMI or plasma insulin levels. IGF1R signaling can be activated during 
elevated insulin and has been linked to reduced apoptosis and cancer progression in a number of organs, 
including the intestine 
77,112,243
. Thus, we hypothesized that patients with adenomas would have up-
regulated IGF1R mRNA expression in their normal rectal mucosa, particularly in those with high plasma 
insulin. Unexpectedly, we found that cases had significantly lower IGF1R mRNA levels than controls, 
and the odds of having colorectal adenomas diminished with increasing IGF1R mRNA expression. We 
considered whether elevated insulin could be linked to the reduced IGF1R mRNA in cases, since elevated 
insulin is known to down-regulate IGFBP1 resulting in higher levels of free circulating IGF1 that can 
down-regulate IGF1R 
153,242,252
. However, the association between decreased IGF1R mRNA and presence 
of adenomas persisted even after adjusting for plasma insulin, suggesting that the reduced IGF1R mRNA 
observed in cases was not merely a result of elevated plasma insulin in this group. We next tested for 
interactions between mRNA levels and BMI or plasma insulin that may impact case status. We found a 
significant interaction between IR-A:IR-B ratio and plasma insulin, where increased IR-A:IR-B ratio was 
associated with increased colorectal adenoma risk in patients with high plasma insulin compared to those 
with low plasma insulin. This suggests that circulating insulin levels may play an important role in 
influencing tumor risk associated with high IR-A:IR-B expression, and that more attention should be 
given to the impact of hyperinsulinemia on relative tissue expression of these IR isoforms.   
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Insulin has long been known to down-regulate its own receptor by negative feedback to properly 
regulate glucose uptake in a number of tissues 
253-257
, and some evidence suggests that hyperinsulinemia 
and insulin resistance can impact isoform expression 
258-261
. Insulin can also down-regulate IGF1R, 
potentially by increasing levels of free IGF1 in plasma 
244,251,252
. Down-regulation of IGF1R transcript in 
situations of high insulin has been described in skeletal muscle of diabetic db/db mice, where reduced 
Igf1r mRNA relative to normoglycemic littermates was associated with increased Igf1r promoter 
methylation 
262
. These numerous lines of evidence for negative feedback effects of elevated insulin are 
supported by the present study showing that in adenoma-free controls, levels of IGF1R and IR mRNAs, 
and IR-A:IR-B ratios each negatively and significantly correlated with plasma insulin. Qualitative 
analysis of IR isoforms suggested that reduced IR-A:IR-B ratio in controls with high plasma insulin 
appeared to be due primarily to increased IR-B. Patients with adenoma differed from controls in that only 
IGF1R mRNA levels significantly and negatively correlated with insulin, and for IR-A:IR-B mRNA 
ratios there was actually a trend for a positive correlation with insulin. This suggests a difference in the 
relationship between plasma insulin and IR mRNA levels or IR-A:IR-B mRNA ratios in cases versus 
controls that may be relevant to mechanisms underlying adenoma risk.  
IR isoforms in humans have been studied primarily in breast and prostate cancers and it is well 
established that IR-A exerts proliferative actions and is overexpressed in tumor tissue 
90,92,101,107
. However, 
little is known about the relative expression of IR isoforms in normal gastrointestinal organs including the 
colorectum. Our findings that mean levels of IR-A mRNA are about 2 fold higher than IR-B mRNA in 
the human rectal mucosa are relevant to normal and aberrant growth of colon epithelium. A predominance 
of IR-A might contribute to the relatively low levels of spontaneous colonocyte apoptosis
232
 and increased 
susceptibility to insulin-mediated reductions in apoptosis. Our recent publication demonstrated a switch 
from predominance of IR-A in proliferative intestinal stem or progenitor cells to IR-B predominance in 
differentiated enterocytes 
97
. Furthermore, IR-B expression was reduced in mouse pre-cancerous 
adenomas versus normal colon and was dramatically reduced in aggressive, poorly differentiated human 
CRC cell lines versus differentiated CRC cells 
97
. Consistent with this finding, other studies have recently 
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shown that the relative mRNA levels of IR-A versus IR-B are elevated in both tumor and grossly normal 
adjacent tissue of human breast and prostate, compared to purely benign tissue 
263,264
. However, whether 
IR isoform expression is altered in normal colorectum in the presence or absence of pre-malignant lesions 
had not to our knowledge been investigated previously. Our study suggests that among patients in the 
upper half of plasma insulin, those with adenomas had higher mean IR-A:IR-B ratio in their normal rectal 
mucosa compared to controls, which appeared to result from decreased IR-B and maintained IR-A as 
observed by qualitative examination. These data were supported by logistic regression analyses, which 
showed that increasing IR-A:IR-B ratios predicted adenomas in patients with elevated plasma insulin. A 
limitation of these findings is that they resulted from a subgroup comparison, in a relatively small number 
of patients. However, they do suggest that the relationship between plasma insulin and relative IR-A:IR-B 
expression in normal tissues should be further explored, as they may be relevant to improved 
understanding of the roles of hyperinsulinemia and impact of IR isoforms on colorectal tumorigenesis. 
A limitation of this study is that alterations in receptor mRNA levels do not necessarily reflect 
changes in protein expression and phosphorylation, as increased activation of IGF1R and IR has been 
reported in cancer 
265,266
. This is particularly difficult to address for IR-A due to the lack of available 
antibodies to permit immunohistochemistry or western immunoblot for this isoform. We chose to analyze 
RNA because sufficient RNA for evaluation of receptor levels is readily obtained from biopsies but we 
recognize the limitation with regard to predicting protein expression or activation. Another limitation of 
our study is the lack of access to actual adenomas as these are considered clinical specimens and were not 
available to us for research. Recent findings from our group using pre-clinical adenoma models provided 
evidence for increased IR-A:IR-B ratios in colon adenomas relative to normal colon mucosa in mice 
97
, 
but whether this is altered in humans and in the context of elevated plasma insulin needs further 
investigation. An additional limitation is that the differences in mean receptor mRNA expression across 
patient groups in this study are relatively small. Despite these limitations, the potential significance of our 
observations is highlighted by the growing interest in the role of the insulin/IGF pathway in cancer and 
IR/IGF1R inhibitors as potential therapies 
145,148,149
. To date, IR and IR isoforms have been understudied 
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in the gastrointestinal tract, and our work suggests that further studies focusing on these receptors and 
relative IR-A and IR-B expression are needed to better understand their roles in initiation and 
pathophysiology of colorectal pre-cancerous lesions. Therefore, our previous and current work indicates 
that additional attention to the relative expression levels and biological roles of IR-A and IR-B is 
warranted.    
Overall, this is to our knowledge the first study to show that the presence of colorectal adenomas 
is associated with decreased IGF1R mRNA and, during elevated plasma insulin, increased IR-A:IR-B 
mRNA ratio in normal rectal mucosa. Particularly, our data raise the important possibility that high IR-
A:IR-B mRNA ratio may contribute to colorectal adenoma initiation during elevated plasma insulin. In 
addition, reduced IGF1R expression and increased relative expression of IR-A:IR-B in normal mucosa 
should be further investigated as potential predictive biomarkers of pre-malignant colorectal lesions.  
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Tables and Figures 
Table 2.1: Descriptive characteristics of study participants. 
 Variable Control Case P* 
Age (mean (se)) 55.4 (0.7) 55.5 (0.7) 0.92 
Race (n (%)) 
   
     White 76 (92) 79 (84) 0.17 
     Black 7 (8) 15 (16) 
 
Sex (n (%)) 
   
     Female 41 (48) 43 (45) 0.66 
     Male 44 (52) 53 (55) 
 
BMI (n (%)) 
   
     Normal 45 (48) 49 (49) 0.98 
     Overweight 29 (31) 29 (29) 
 
     Obese 20 (21) 21 (21) 
 
Physical Activity in MET-minutes 
per week (mean (se)) 
2,981 (341) 2,485 (263) 0.25 
Apoptosis (mean (se)) 1.42 (0.12) 1.08 (0.06) 0.008
†
 
Plasma insulin (mean μU/ml (se)) 7.1 (0.8) 10.8 (1.7) 0.055 
Calories (mean (se)) 2,101 (88) 1,949 (79) 0.20 
Waist / Hip ratio (mean (se)) 0.908 (0.01) 0.915 (0.01) 0.54 
BMI: body mass index 
MET: metabolic equivalent of task 
*Chi square for age, race and gender and student’s t-test for remaining variables 
†Significant at P < 0.05 
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Table 2.2: Mean expression of IGF1R, IR, and IR-A:IR-B mRNAs in controls versus cases overall 
and grouped by BMI and plasma insulin status. 
 Variable Subgroup n 
Control 
 mean (se)  
n 
Case 
mean (se) 
P* 
IGF1R 
Everyone 98 1.04 (0.03) 
 
100 0.90 (0.02) 0.0003
†
 
BMI 
Normal 
Ovt/Ob 
45 
49 
1.06 (0.05) 
1.00 (0.04)  
49 
50 
0.91 (0.04) 
0.88 (0.03) 
0.02
†
 
0.01
†
 
Insulin 
Low 
High 
48 
47 
1.09 (0.05) 
0.97 (0.04)  
36 
43 
0.93 (0.03) 
0.88 (0.03) 
0.007
†
 
0.09 
IR 
Everyone 98 1.17 (0.03) 
 
100 1.17 (0.06) 0.94 
BMI 
Normal 
Ovt/Ob 
45 
49 
1.14 (0.05) 
1.17 (0.04)  
49 
50 
1.18 (0.11) 
1.15 (0.04) 
0.78 
0.82 
Insulin 
Low 
High 
48 
47 
1.24 (0.05) 
1.08 (0.04)  
36 
43 
1.12 (0.05) 
1.12 (0.04) 
0.10 
0.51 
IR-A:IR-B 
Everyone 98 1.96 (0.04) 
 
100 1.96 (0.03) 0.94 
BMI 
Normal 
Ovt/Ob 
45 
49 
2.01 (0.07) 
1.91 (0.04)  
49 
50 
1.96 (0.05) 
1.95 (0.03) 
0.52 
0.48 
Insulin 
Low 
High 
48 
47 
2.07 (0.07) 
1.85 (0.04)  
36 
43 
1.95 (0.05) 
2.01 (0.04) 
0.18 
0.006
†
 
*Student’s t-test 
†Significant at P < 0.05 
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Figure 2.1: Representative gels showing IR-A and IR-B mRNAs in cases and controls with low and 
high plasma insulin. 
Controls with high insulin have decreased IR-A:IR-B ratios compared to controls with low insulin, 
potentially due to increased IR-B and maintained IR-A. Among patients with high insulin, cases have 
higher IR-A:IR-B ratios than controls, and this appears to result from decreased IR-B and unaltered IR-A. 
Samples were run in groups of 19 per gel, and representative images were obtained from different 
originals or multiple fields from the same image.    
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Table 2.3: ORs and 95% CIs for the association between colorectal adenomas and IGF1R, IR, and 
IR-A:IR-B mRNA expression. 
 Variable n (Control/Case)  OR* (95% CI) P* 
IGF1R 
   
Q1 25/46 1.0 (Reference) - 
Q2 25/23 0.5 (0.2-1.1) 0.07 
Q3 25/19 0.4 (0.2-0.9) 0.02
†
 
Q4 23/12 0.3 (0.1-0.7) 0.004
†
 
IR 
   
Q1 25/26 1.0 (Reference) - 
Q2 24/28 1.1 (0.5-2.4) 0.77 
Q3 25/30 1.2 (0.5-2.5) 0.71 
Q4 24/16 0.6 (0.3-1.5) 0.30 
IR-A:IR-B 
   
Q1 25/29 1.0 (Reference) - 
Q2 24/20 0.7 (0.3-1.6) 0.42 
Q3 25/23 0.8 (0.4-1.7) 0.56 
Q4 24/28 1.0 (0.5-2.2) 0.99 
 *Odds of being a case 
 †Significant at P < 0.05 
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Table 2.4: Association between colorectal adenomas and IGF1R, IR, and IR-A:IR-B mRNA 
expression influenced by BMI and plasma insulin. 
   P for interaction 
Variable BMI  
(Normal vs. Ovt/Ob) 
Insulin 
(Low vs. High) 
IGF1R 0.78 0.47 
IR 0.74 0.11 
IR-A:IR-B 0.34 0.005
†
 
 †Significant at P < 0.05 
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Figure 2.2: Increased IR-A:IR-B ratios predicts adenomas in patients with high plasma insulin. 
As IR-A:IR-B ratios increase, patients with high plasma insulin are more likely to have colorectal 
adenomas than patients with low plasma insulin. 
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Table 2.5: Correlation between plasma insulin and IGF1R, IR, and IR-A:IR-B mRNA expression. 
 Plasma insulin 
  Variable 
Controls (n=95)  Cases (n=79) 
r* P  r* P 
IGF1R -0.21 0.045
†
 
 
-0.30 0.01
†
 
IR -0.26 0.01
†
 
 
-0.14 0.21 
IR-A:IR-B -0.31 0.002
†
 
 
0.21 0.06 
 *Spearman’s correlation coefficient  
 †Significant at P < 0.05 
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CHAPTER 3: IMPACT OF INTESTINAL EPITHELIAL INSULIN RECEPTOR LOSS ON 
AOM-DSS INDUCED COLON TUMORIGENESIS 
 
Introduction 
Colorectal cancer (CRC) is the second most common cause of cancer death in the United 
States
146
. A growing body of evidence links increased risk of colorectal carcinogenesis to chronic 
inflammation resulting from inflammatory bowel disease (IBD) and to obesity and insulin resistance 
60,210
. 
The insulin and insulin-like growth factor (IGF) signaling pathway has been implicated in risk of CRC 
243
, 
but a major unanswered question is whether the insulin receptor (IR) or the related IGF1 receptor 
(IGF1R) mediates this risk. IR exists as IR-B and IR-A isoforms. IR-B is considered the primary mediator 
of the metabolic actions of insulin, although growing evidence in mammary epithelium and our recent 
findings in colon epithelial cells or cancer cell lines indicate that IR-B induces cell differentiation 
96,97
. IR-
A binds IGFs as well as insulin and shares proliferative and anti-apoptotic roles with IGF1R 
90,91,107
. 
IGF1R mediates anti-apoptotic and trophic actions of IGF1 or IGF2 and has been implicated in cancer of 
many organs, including the colon 
78,118,140,141,145,265
. Due to reports of elevated IR-A expression in cancer 
cells and findings that IR-A promotes tumor progression when IGF1R is pharmacologically inhibited or 
deleted, IR has been viewed as a culprit in promoting cancer growth 
90,97,146,147,263,264,267
. Opposing this 
evidence is a study showing that knockdown of IR-A in SW480 colon cancer cells increased viability and 
enhanced activation of the related oncogenic IGF1R 
104
. This raises the intriguing possibility that IR may 
limit oncogenic IGF1R signaling.  
Insulin resistance during hyperinsulinemia, obesity, or type 2 diabetes involves impaired insulin 
signaling through IR-B in insulin-target organs such as liver, skeletal muscle, and adipose tissue, which 
show higher expression of IR-B relative to IR-A 
93,107
. In multiple human cohorts, we and others have 
linked hyperinsulinemia to increased risk of colorectal adenomas and cancer 
155,186,187,268,269
. Whether this 
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risk involves insulin acting on IGF1R or IR-A when IR-B signaling is impaired, as occurs in insulin 
resistance, is unknown. The goal of the current study was to evaluate the impact of loss of IR function in 
the intestinal epithelium on colon tumorigenesis. We hypothesized that intact IR signaling normally 
attenuates the tumor-promoting actions of IGF1R, and IR loss would therefore favor tumor formation. 
Here, we used a mouse model of disrupted insulin signaling in all intestinal epithelial cells (IEC) of small 
intestine and colon via villin-Cre (VC) recombinase-mediated deletion of the IR gene (VC-IR
Δ/Δ
) 
270
. 
These mice and littermate controls with loxP-modified but intact IR (WT-IR
fl/fl
) were subjected to 
azoxymethane (AOM) and dextran sodium sulfate (DSS) treatment which lead to inflammation-induced 
colon cancer. In this preliminary study performed in two independent cohorts of WT-IR
fl/fl
 and VC-IR
Δ/Δ
 
mice, we found that deletion of IR in colon epithelial cells (CECs) dramatically increases tumor number 
in vivo and enhances growth of tumor-derived CECs in a matrigel culture system. This novel evidence 
that loss of IR promotes colon tumorigenesis indicates that maintained IR signaling may be essential for 
CRC prevention. 
 
Materials and methods 
Animals 
Mice with loxP sites flanking exon 4 of the Insr gene (IR
fl/fl
) were provided and described by Dr. 
Ronald Kahn’s group 271. Mice with IEC-specific IR deletion were generated by crossing IRfl/fl mice with 
transgenic mice expressing Cre recombinase under the control of the villin promoter (The Jackson 
Laboratory, Bar Harbor, ME) 
272
. All mice were on a C57BL/6 background and co-housed littermate pairs 
with intact but floxed IR (WT-IR
fl/fl
) or villin-Cre (VC)-mediate disruption of IR (VC-IR
Δ/Δ
) were used in 
this study. Genotyping on tail DNA was performed using published protocols 
273
.  All mice were housed 
in a pathogen-free animal facility at the University of North Carolina (Chapel Hill, NC) and given food 
and water ad libitum. All animal experiments were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of North Carolina. 
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AOM-DSS treatment, tissue harvest, and histology 
The experimental design is illustrated in Figure 3.1 and was adapted from previously published 
protocols, which reproducibly induce colon tumors in C57BL6 mice 
75,274
. Male and female WT-IR
fl/fl
 and 
VC-IR
Δ/Δ
 mice were given a single intraperitoneal (i.p.) injection of AOM (10 mg/kg body weight, MRI 
Chemical Carcinogen Repository). A week later, a subset of mice were subjected to 3 cycles of 2% DSS 
(TbD Consultancy AB) in water for 5 days followed by a 14-day recovery period where mice were given 
water. At the end of the 3
rd
 recovery period, all animals were euthanized with isoflurane (Baxter) and 
cervical dislocation. Colons were removed and flushed with cold 1x phosphate-buffered saline (PBS) pH 
7.4 and opened longitudinally. The number of tumors was quantified by two researchers blinded to animal 
genotype. Individual tumors from the middle portion of the distal colon were collected for RNA 
extraction or culture experiments. The remaining regions of the distal colon were fixed in 10% zinc 
formalin overnight for histology. Fixed colon tissue was embedded in paraffin and longitudinal sections 
were stained with hematoxylin and eosin (H&E). Histological sections were visualized with an Axio 
Imager.A2 bright field microscope (Zeiss) and a ProgRes CF Scan camera (Jenoptik). 
 
Conditional reprogramming of colon tumor epithelial cells (CR-CTEC) 
Protocols for preparation and maintenance of CR-CTEC were adapted from Liu et al., 2012 
64
. 
Dispersed CECs obtained from WT-IR
fl/fl
 and VC-IR
Δ/∆
 tumors were plated on mitotically inactive 3T3-J2 
feeder cells in F-medium containing 10 μM Y27532 and Sato growth factors (Noggin, EGF, and R-
Spondin) 
275
. Sato additives were withdrawn 1 day after plating or passage and CR-CTEC were 
maintained in regular F medium thereafter. 
 
3D matrigel culture 
Feeders were removed from the wells using TrypLE Express Enzyme (Life Technologies) and 
discarded. CR-CTEC were removed by a second incubation in TrypLE Express, washed in F medium, 
and resuspended in 50 μl of Matrigel Matrix Growth Factor Reduced (BD Biosciences) at a density of 
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5,000 cells per well of a 24-well plate. The same plating and maintenance conditions described above 
were used. Plates were imaged using a using an inverted bright field microscope with an incubation 
chamber (Olympus IX83). Cells started to form spheroids/tumorspheres on day 2 after plating. Diameter 
was measured on day 8 using Image J software (National Institutes of Health). Tumorspheres continued to 
grow and started to form organoids with crypt-like structures on days 10-11 post-plating. The number of 
organoids formed was quantified on day 15 and organoids were harvested for RNA and DNA extraction. 
Genotyping on organoid DNA for floxed and VC-recombined IR gene was performed as previously 
described 
273
. Organoids were passaged and treated with 0 or 10 mM metformin (Aurobindo Pharma) the 
following day. Metformin was added in F medium, which was replaced every two days. Tumorspheres 
were imaged at days 2 and 4 after the start of metformin treatment and diameter was measured as 
described above.    
 
IGF1 treatment of tumor CEC monolayers and western blot 
CR-CTECs were plated on 12-well transwell plates with F medium plus 10 µM Y-27632 and 
with feeders at the bottom. Cells were allowed to grow for 2 days. Prior to signaling, cells were 
transferred to feeder-free wells and serum-starved for 4 hours in DMEM plus 10 µM Y-27632. 
Stimulation with IGF1 (20 ng/ml, Tercica, Inc) in serum-free DMEM was performed for 20 minutes. An 
IGF1 concentration of 20 ng/ml (2.8 nM) is only able to activate IGF1R and not IR 
103
. Hot Laemmli blue 
buffer was added to treated and untreated transwell filters and protein samples were collected, vortexed, 
and run on a NuPAGE 4–12% Bis-Tris 1.0 mm gel (Life Technologies). Gel was transferred to a 0.45 mm 
pore PVDF membrane (Millipore), which was blocked with Blocker Casein in TBS (Thermo Fisher 
Scientific) for 1 hour. Primary antibodies used were phospho-AKT1 (Ser 473, Cell Signaling), AKT (Cell 
Signaling), and β-actin (Sigma Aldrich). Secondary antibody used was Dylight 800 goat anti-rabbit IgG 
(Thermo Scientific). Protein was visualized with an Odyssey CLx Infrared Imager (Version 3, LI-COR) 
and band intensity was measured by densitometry with ImageJ software (National Institutes of Health). 
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RNA extraction, reverse transcription, and quantitative real-time PCR 
RNA was isolated from colon tumors and organoids using the RNeasy kit (Qiagen) and cDNA 
was synthesized using the High Capacity cDNA Reverse Transcription Kit and RNase inhibitor (Applied 
Biosystems) according to the manufacturer’s protocol. Quantitative real-time polymerase chain reaction 
(qRT-PCR) was performed using the 7500 Real-Time PCR System (Applied Biosystems) and 
primer/probes for Igf1 (Mm00439560_m1), Igf2 (Mm00439564_m1), Stat3 (Mm01219775_m1), Tnf 
(Mm00443258_m1), and Actb as the invariant control (Mm00607939_s1). Samples were run in 
duplicates and concentrations were determined based on a standard curve made with cDNA pooled from 
all samples studied.  
 
Statistical analysis 
Data were collected from two independent experiments and expressed as mean ± SEM. For WT-
IR
fl/fl
 and VC-IR
Δ/Δ
 groups, n ≥ 7 for survival and tumor number, and n = 7 for tumor gene expression 
data. Tumorspheres and organoids used during in vitro experiments were prepared from tumor cells from 
only 1 pair of animas (n = 1), but replicate studies were performed on lines established from these tumors. 
Ongoing studies aim to increase the sample size for the cell culture experiments. Survival data were 
analyzed using the Log-rank (Mantel-Cox) test. Tumor number in WT-IR
fl/fl
 versus VC-IR
Δ/Δ
 groups were 
compared using unpaired t-test.  Gene expression in tumor tissue was analyzed by paired t-test. All 
analyses were performed using GraphPad Prism 6 software (La Jolla, CA) and P < 0.05 was considered 
statistically significant. 
 
Results 
Loss of IR in CECs leads to decreased survival and increased number of colon tumors after AOM-
DSS treatment 
WT-IR
fl/fl
 and VC-IR
Δ/∆
 mice were given a single AOM injection followed by three DSS cycles, 
each separated by 14 days of water drinking, and euthanized 14 days after the last DSS cycle. Survival 
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was significantly decreased in the VC-IR
Δ/∆
 group (P = 0.03), particularly during the last two weeks of the 
experiment (Figure 3.2A). Consistent with our hypothesis, VC-IR
Δ/∆
 mice had significantly more tumors 
than WT-IR
fl/fl 
littermates (18.3 ± 1.4 versus 9.3 ± 1.6, P = 0.002, Figure 3.2B-D). These data indicate that 
loss of IR in CECs promotes colorectal tumorigenesis and decreases survival following AOM-DSS 
treatment.  
 
Preliminary data indicate that loss of IR in CECs promotes tumorsphere and organoid formation 
and IGF1-induced activation of AKT in vitro 
Confluent WT-IR
fl/fl
 and VC-IR
Δ/∆
 CR-CTEC colonies were removed from feeders and plated in 
matrigel. Spheroid/tumorsphere diameter was measured on day 8 and the number of organoids formed 
was quantified on day 15 post-plating. Compared with the WT-IR
fl/fl
 group, VC- IR
Δ/∆ 
tumorspheres had a 
much larger mean diameter (686.2 ± 81.6 μm versus 334.8 ± 45.6 μm) and formed more organoids (19 
versus 6, Figure 3.3A-C). Importantly, organoids from VC-IR
Δ/∆
 mice retained complete VC-induced IR 
gene disruption, validating stability and epithelial phenotype (Figure 3.3D). We next asked if the 
remaining IGF1R would cause VC-IR
Δ/∆
 CECs to be more responsive to IGF1 stimulation. To address 
this question, we plated CR-CTEC onto transwells and added 20 ng/ml IGF1. After 20 minutes, IGF1 
treatment induced an increase in AKT phosphorylation of WT-IR
fl/fl
 tumor cells. Interestingly, IGF1-
induced AKT phosphorylation was further increased in VC-IR
Δ/∆
 tumor cells (Figure 3.3E-F). Together, 
these preliminary in vitro data indicate that tumor CECs lacking IR have an intrinsic increase in growth 
capacity and enhanced sensitivity to IGF1-induced activation of AKT relative to tumor CECs with intact 
IR. 
 
Preliminary results show that treatment with the insulin-sensitizing agent metformin decreases 
growth rate of VC-IR
Δ/∆
 tumorspheres to basal levels observed in the WT-IR
fl/fl
 group  
Tumor CECs in matrigel were treated with 0 or 10 mM metformin and diameter of tumorspheres 
formed were measured 2 and 4 days after the start of treatment (Figure 3.4). Metformin is an insulin-
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sensitizing drug widely used for the treatment of diabetes and multiple studies have reported that 
metformin has strong anti-tumorigenic effects 
200
. Metformin treatment on WT-IR
fl/fl
 tumor CECs reduced 
tumorsphere diameter by 2.1 ± 0.4 fold on day 4. In the VC-IR
Δ/∆
 group, tumorsphere diameter was 
dramatically decreased by 2.7 ± 0.4 fold and growth rate was comparable to that observed in the untreated 
WT-IR
fl/fl
 group (Figure 3.4). These preliminary data indicate that when IR signaling is lost, metformin 
may be able to reduce tumor cell growth rate to that of cells with intact IR.   
 
Igf1 and Igf2 mRNAs in tumor tissue are increased in VC-IR
Δ/∆
 versus WT-IR
fl/fl
 mice and tumor 
organoids show a similar expression pattern   
Quantitative real-time PCR was performed on colon tumor tissue and organoids from WT-IR
fl/fl
 
and VC-IR
Δ/∆
 mice. Igf1 and Igf2 are known to be overexpressed in cancer 
82,243
. Tumor tissue from VC-
IR
Δ/∆
 mice had significantly higher Igf2 and a non-significant trend towards increased Igf1 mRNA levels 
relative to WT-IR
fl/fl
 animals (Figure 3.5A-B). Levels of the pro-inflammatory mediators Stat3 and Tnf 
(which encodes for TNF-α) did not change across genotypes (Figure 3.5C-D). This gene expression 
profile appeared to be recapitulated in organoids derived from tumor cells. Our data suggest that increased 
local production of IGF1 and IGF2 may contribute to enhanced colon tumor growth in VC-IR
Δ/∆
 mice 
likely via IGF1R signaling. 
 
Discussion 
This study aimed to directly define the role of IR in colorectal tumorigenesis using mice with 
IEC-specific deletion of IR and the AOM-DSS model of inflammation-associated CRC. Our novel data 
showed that loss of IR in CECs dramatically enhanced colon tumor development in vivo and preliminary 
data indicated that IR loss promotes growth of tumor cells in vitro. Defining mechanisms linked to the 
tumor-promoting effects of IR loss is highly relevant to understanding whether and how diminished 
insulin signaling in CECs may impact risk of colon adenomas or cancer in humans. 
Numerous studies have reported increased expression of the IR-A isoform in cancer and linked 
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IR-A to tumor growth 
90,92,107,267,276
. However, it is important to note that a majority of reports use 
traditional non-quantitative PCR to demonstrate that IR-A is the primary IR isoform expressed and less 
evidence (e.g. by qRT-PCR or assays at the protein levels) confirms quantitative increases in IR or IR-A 
expression. Our recent findings demonstrated reduced expression of total IR mRNA in small intestine and 
colon tumors of Apc
Min/+
 mice was due to decreased IR-B 
97
. In addition, we demonstrated that IR-B 
expression is low or barely detectable in aggressively growing human colon cancer cell lines which 
express IR-A 
97
. In a recent human study, we also showed that reduced IR-B predicts increased colorectal 
adenoma risk in humans with elevated plasma insulin 
269
.  Brierley et al. found that knockdown of IR-A in 
a CRC cell line that does not express IR-B potentiated IGF1R signaling and cancer cell viability 
104
. 
These data, our current data that deletion of IR in CECs promotes colon tumorigenesis in vivo, and our 
previous findings that reductions in IR-B accompany and predict risk of pre-cancerous adenomas
269
 
strongly support a protective effect of IR against colon tumor growth. Furthermore, our preliminary in 
vitro data showed that tumor CECs with deleted IR had enhanced growth in matrigel relative to CECs 
with intact IR, indicating that loss of IR confers an intrinsic growth advantage to colon tumor epithelial 
cells.   
To directly test if IR loss enhanced IGF1R activation, we treated WT-IR
fl/fl
 and VC-IR
Δ/∆
 tumor 
cells grown on transwells with a dose of IGF1 considered sufficient to activate IGF1R but not IR
103
. This 
preliminary experiment showed that phosphorylation of AKT, a key downstream mediator of IGF1R and 
IR signaling, was increased in VC-IR
Δ/∆
 versus WT-IR
fl/fl
 tumor CECs treated with IGF1. This suggests 
that tumor cells lacking IR are more responsive to IGF1 treatment, which likely reflects enhanced 
signaling through the remaining IGF1R. Furthermore, gene expression analyses in tumor tissue showed 
that, by a yet unclear mechanism, mRNA levels of Igf1 and Igf2 were up-regulated in VC-IR
Δ/∆
 tumors 
relative to WT-IR
fl/fl
 tumors. Therefore, increased local expression of Igf1 and Igf2 could further 
contribute to enhanced activation of IGF1R when IR signaling is lost. The increase in Igf2 is of particular 
interest because the maternal allele of the IGF2 gene is usually silenced by imprinting, and increased 
IGF2 expression due to loss of imprinting is a common event in CRC 
277,278
. Importantly, WT-IR
fl/fl
 and 
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VC-IR
Δ/∆
 organoids showed a similar gene expression pattern, suggesting that the matrigel tumor culture 
system used here may represent a useful tool to study mechanisms of tumor growth in vitro that are 
difficult to address in the intestine in vivo. Together, IGF1R may be hyperactivated due to IR deletion, 
leading to enhanced cell growth and tumorigenesis. Future studies will test whether tumors from VC-
IR
Δ/Δ
 mice exhibit increased proliferation, reduced apoptosis, or activation of other mediators linked to 
IGF1R signaling and test directly if re-expression of IR-B or IR-A or inhibition of IGF1R reduces growth 
of VC-IR
Δ/Δ
 tumor cells. 
Insulin resistance and obesity are associated with impaired activation of AMP kinase (AMPK) 
which is improved by metformin, a widely used anti-diabetic drug with promising protective roles against 
CRC 
279-281
. Our preliminary data demonstrated that metformin decreased growth of both WT-IR
fl/fl
 and 
VC-IR
Δ/Δ
 tumorspheres and restored growth of VC-IR
Δ/Δ
 tumor cells to similar levels as in WT-IR
fl/fl
 
cells. These data suggest that altered AMPK signaling may contribute to enhanced tumor growth when IR 
is dysfunctional. The ability of metformin to reverse enhanced tumor growth due to loss of IR signaling 
has implications for cancer-protective roles in type 2 diabetes.  
In summary, our work provided novel evidence that loss of IR promotes colon tumorigenesis and 
tumor growth in vivo and in vitro. These findings add direct support for a growing body of evidence that 
robust IR signaling may be crucial for improved prevention of colorectal cancer and therefore have major 
clinical relevance. Confirmation that loss of IR promotes colon tumors would highlight the clinical 
significance of strategies to preserve and better monitor IR signaling. Further studies aimed at defining 
mediators of enhanced tumorigenesis due to loss of IR will improve our ability to study the impact of 
impaired IR signaling on risk of pre-cancerous or cancerous lesions in the colon. 
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Figures 
 
Figure 3.1: Experimental design. 
Animals were given a single intraperitoneal injection of AOM followed by 3 treatments consisting of 2% 
DSS for 5 days. Between each DSS treatment, there was a recovery period of 14 days in which the mice 
were given water. Mice were sacrificed 14 days after the third DSS cycle.  
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Figure 3.2: VC-IR
Δ/∆
 mice showed increased mortality and number of colon tumors resulting from 
AOM-DSS treatment. 
(A) Survival curve showing the percent survival for each group over time. Data were analyzed using the 
log-rank (Mantel-Cox) test, P = 0.03. (B) Quantification of colonic tumors in WT-IR
fl/fl
 and VC-IR
Δ/Δ
 
animals. Data expressed as mean ± SEM (n ≥ 7), *P < 0.05, unpaired t-test. C-D: Representative images 
of (C) tumors in fresh colon specimens and (D) H&E images of tumor histology from WT-IR
fl/fl
 and VC-
IR
Δ/Δ
 mice after AOM-DSS treatment (for panel D, 4x objective, black scale bar = 500 μm). 
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Figure 3.3: Loss of IR enhances tumorsphere growth and organoid formation in matrigel and 
promotes IGF1-induced AKT phosphorylation of tumor CECs. 
(A) Representative images showing tumorspheres on day 8 (top row) and organoids on day 15 (bottom 
row) after plating tumor-derived CECs in matrigel (white scale bars = 200 μm, black scale bars = 100 
μm). B-C: Graphs with data for (B) tumorsphere diameter on day 8 and (C) number of organoids formed 
on day 15 post-plating. Data in panel B are representative of 10 tumorspheres per mouse and expressed as 
mean ± SEM. (D) Gel image showing complete villin-Cre-induced recombination of the IR gene in VC-
IR
Δ/Δ
 and not WT-IR
fl/fl
 organoids after passage. E-F: (E) Western blot and (F) protein quantification by 
densitometry indicating enhanced AKT phosphorylation in VC-IR
Δ/Δ
 tumor CECs 20 minutes after 
treatment with 20 ng/ml IGF1.  
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Figure 3.4: Metformin treatment restores growth of VC-IR
Δ/Δ
 tumorspheres to levels observed in 
WT-IR
fl/fl 
tumorspheres. 
(A) Representative images of tumorspheres treated with 0 or 10 mM metformin (Met) for 2 or 4 days (10x 
objective, scale bars = 100 μm). (B) Diameter measured in untreated and treated WT-IRfl/fl and VC-IRΔ/Δ
 
tumorspheres on days 2 and 4 after the start of metformin treatment. Data are representative of ≥ 7 
tumorspheres per group and are expressed as mean ± SEM.  
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Figure 3.5: Colon tumors and organoids from VC-IR
Δ/∆
 mice show increases in Igf1 and Igf2 mRNA 
levels and no change in Stat3 or Tnf mRNAs relative to WT-IR
fl/fl
 mice. 
Gene expression data obtained by qRT-PCR showing mRNA levels of (A) Igf1, (B) Igf2, and the pro-
inflammatory mediators (C) Stat3 and (D) Tnf  in tumor tissue and organoids (harvested 15 days post-
plating) from WT-IR
fl/fl
 and VC-IR
Δ/Δ
 mice. Data for tumor tissue were expressed as mean ± SEM (n = 4), 
*P < 0.05, n.s.: no significance, paired t-test.  
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CHAPTER 4: OBESITY AND THE INSULIN RECEPTOR, BUT NOT THE IGF1 RECEPTOR, 
PROMOTE RESISTANCE OF COLON EPITHELIAL CELLS TO RADIATION-INDUCED 
APOPTOSIS 
 
Introduction  
Obesity affects 35% of the adult population of the United States and 600 million adults 
worldwide 
176,282
. Obesity can lead to hyperinsulinemia and insulin resistance, which can progress to type 
2 diabetes (T2D), and these metabolic disorders have been strongly linked to risk of a number of cancers 
210,244,283,284
, including colorectal cancer (CRC) 
187,241,285,286
. Hyperinsulinemia is a compensatory response 
to impaired insulin signaling and may contribute to increased CRC risk, decreased response to 
chemotherapy or radiotherapy, and increased CRC recurrence and mortality associated with obesity and 
T2D 
189-192,287
. However, the mechanisms underlying CRC risk and poor treatment outcome during obesity 
or hyperinsulinemia remain unclear.  
Current views support the concept that tumors can arise due to survival and subsequent expansion 
of genetically damaged stem or progenitor cells 
288,289
. Apoptosis is a programmed cell death that is used 
by the body to eliminate unwanted cells with DNA damage, which may otherwise contribute to neoplasia. 
The frequency of basal, spontaneous apoptosis in the non-challenged small intestinal epithelium is very 
low 
230,233,235
. Spontaneous apoptosis in the colonic epithelium is even rarer, consistent with relatively 
high levels of the anti-apoptotic protein BCL-2 and low levels of the pro-apoptotic p53 
231-234
. Therefore, 
models of DNA damage induced by low-dose ionizing radiation (1-6 Gy) with evaluation of maximal 
apoptosis at 3-4.5 hours post-radiation have served as useful systems to study apoptosis in the intestinal 
epithelium 
113,230,235,290
. Whereas in the small intestine both spontaneous and radiation-induced apoptosis 
occur primarily at the crypt base where stem cells reside, apoptosis in the colon is scattered along the 
crypt and is not associated with the position of putative stem cells 
230,233
.
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   Our group and others have reported that insulin-like growth factor 1 (IGF1) inhibits radiation-
induced apoptosis in the intestinal crypts 
113,235,290
. IGFs potently stimulate intestinal growth 
112,119,123,127
 
and are widely considered mediators of survival or proliferation of cancer cells 
180,243
. Levels of 
bioavailable IGF1 can be increased by elevated plasma insulin, which inhibits hepatic production of IGF 
binding protein 1 (IGFBP1) 
153,291
. Both insulin and IGF1 can exert mitogenic and anti-apoptotic actions 
in normal and cancer cells via the insulin receptor (IR) or the IGF1 receptor (IGF1R) 
77,86,119,243
, which 
belong to the receptor tyrosine kinase family and are highly homologous in structure 
83
. Studies on the 
specific roles of IGF1R versus IR in proliferation and anti-apoptosis in the context of elevated insulin 
have been challenging because dependent on their levels, IGF1 and insulin can each activate both IGF1R 
and IR. 
Traditionally, IGF1R has been viewed as the main mediator of the trophic, anti-apoptotic, and 
pro-tumorigenic actions of IGFs and IGF1R overexpression has been reported in colorectal 
adenocarcinomas 
78,79,141,142,292
. In contrast, IR has been considered to play a larger role in mediating the 
metabolic actions of insulin 
80,271,293
. However, the IR gene undergoes pre-mRNA splicing that leads to 
expression of two functionally-distinct IR isoforms, IR-A and IR-B. IR-A lacks exon 11, mediates growth 
of fetal and tumor cells, and binds both insulin and IGFs, particularly IGF2, with high affinity 
90,92
. IR-B 
contains exon 11 which alters the structure of the ligand binding α-subunit and confers high affinity for 
insulin versus IGFs 
90,107
. IR-B is considered the major mediator of insulin action on nutrient storage and 
metabolism 
77,107
. A concept that IR may promote tumor growth is based on evidence that IR-A is highly 
expressed in cancer cells or tumors and studies showing that IR promoted tumor cell survival or growth 
when IGF1R was inhibited 
97,107,146,147,263,264
. In contrast, knockdown of IR-A in the colon cancer cell line 
SW480 promoted cell viability and this was associated with enhanced IGF1R phosphorylation 
104
.  
Our prior human studies found that high plasma insulin and low apoptosis in normal rectal 
mucosa were consistently associated with colorectal adenomas in multiple patient cohorts 
155,165,186,294
. 
Therefore, defining the roles of obesity-associated hyperinsulinemia and IGF1R versus IR in promoting 
survival of genetically damaged colon epithelial cells (CECs) is relevant to mechanisms by which obesity 
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may promote risk of early stage colon tumors. In this study, we used a model of high fat diet (HFD)-
induced obesity and hyperinsulinemia challenged with DNA damage caused by low-dose radiation to 
directly evaluate the impact of obesity on apoptosis of genetically damaged CECs. These studies were 
performed in mice with genetic disruption of IGF1R or IR in intestinal epithelial cells (IEC) and 
littermate controls to more directly define the roles of IGF1R or IR in radiation-induced CEC apoptosis 
during obesity and hyperinsulinemia. We hypothesized that obesity/hyperinsulinemia would lead to 
decreased apoptosis of genetically damaged CECs. We also hypothesized that any anti-apoptotic effects 
of obesity and hyperinsulinemia would be prevented or attenuated by IGF1R deletion and not IR deletion. 
Our results provide novel evidence that obesity and hyperinsulinemia promote reduced apoptosis of CECs 
following DNA damage. Surprisingly, IR but not IGF1R deletion increased apoptosis in lean and obese 
mice but did not prevent the reduction in apoptosis observed during obesity.   
 
Materials and methods  
Animals 
Mice with loxP sites flanking exon 3 of the Igf1r gene (IGF1R
fl/fl
) were obtained from Dr. Argiri 
Efstratiadis (Columbia University, NY) and have been described by Xuan et al. and Zhang et al. 
295,296
. 
Mice with loxP sites flanking exon 4 of the Insr gene (IR
fl/fl
) were provided by Dr. Ronald Kahn and 
described by Brüning et al. 
271
. To generate mice with IEC-specific IGF1R or IR gene disruption, 
IGF1R
fl/fl
 and IR
fl/fl
 mice were crossed with villin-Cre (VC) mice expressing a Cre recombinase transgene 
driven by the villin promoter (The Jackson Laboratory, Bar Harbor, ME) 
272
. The VC transgene is 
expressed throughout both small intestinal and colonic epithelium. All mice were on a C57BL/6 
background. Study animals were derived by cross-breeding WT-IGF1R
fl/fl
 and VC-IGF1R
Δ/Δ
 mice or WT-
IR
fl/fl
 and VC-IR
Δ/Δ
 mice. Genotyping on tail DNA was performed as previously described 
273,296
. Animals 
were housed in a pathogen-free facility at the University of North Carolina (Chapel Hill, NC), and food 
and water were provided ad libitum. All animal experiments were approved by the Institutional Animal 
Care and Use Committee (IACUC) of the University of North Carolina. 
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Diet-induced obesity 
WT-IGF1R
fl/fl
 and VC-IGF1R
∆/∆
 mice or WT-IR
fl/fl
 and VC-IR
∆/∆
 male mice (10-12 week old) 
were assigned to either a standard rodent chow control (CTL) diet (14% Kcal from fat) or high fat diet 
(HFD, 45% Kcal from fat, Research Diets, New Brunswick, NJ). In C57BL/6 mice this HFD leads to 
obesity, hyperinsulinemia, and insulin resistance within 14-16 weeks of onset of diet 
67,297
. Male mice 
were used because our prior studies have demonstrated more reproducible and consistent development of 
obesity and hyperinsulinemia in males versus females on C57BL/6 background. In the current study, after 
16 weeks on CTL diet or HFD, blood was collected from the tail vein after an overnight fast and plasma 
was isolated by centrifugation at 600 rcf for 6 minutes. Fasting blood glucose levels were measured using 
a OneTouch Ultra 2 glucometer (LifeScan, Milpitas, CA). Mice were given CTL diet or HFD for two 
additional weeks before radiation and euthanasia.  
 
Radiation and tissue harvest 
After 18 weeks on diets, mice were anesthetized with isoflurane (Baxter, Deerfield, IL) and 
abdominally irradiated with a single dose of 5 Gy using an XRad 320 (Precision X-Ray, North Branford, 
CT) at a rate of 1.07 Gy/min. Euthanasia was carried out with a lethal dose of Nembutal (150 μg/g) given 
via intraperitoneal injection 4 hours post-radiation, a time corresponding to maximal apoptosis of (IEC) 
after radiation-induced DNA damage 
12,113,237,298,299
. The colon was collected and flushed with cold 1x 
phosphate-buffered saline pH 7.4. All mesentery fat was removed and discarded. Length and weight of 
entire colon were recorded. As illustrated in Figure 4.1, for the first group of mice (n ≥ 5), entire colon 
was splayed open and fixed in 4% paraformaldehyde (PFA) overnight for histological scoring of 
apoptosis. For the second group (n ≥ 3), the most proximal and distal ~1-cm segments of the colon were 
fixed in 10% zinc formalin overnight to confirm histological apoptosis data obtained in the first group. 
The remaining of the tissue was splayed opened and 3-4 cm of the distal colon were used for CEC 
isolation for gene and protein expression experiments. The distal colon was used for histological and 
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biochemical analyses because in mouse models of CRC, tumors develop mainly in the distal colon and 
very rarely in the proximal portion.  
 
Blood and plasma measurements 
Fasting plasma insulin was measured by ELISA (Mercodia, Uppsala, Sweden). Insulin sensitivity 
was estimated by calculating homeostatic model assessment (HOMA) values using the formula Fasting 
Glucose (mmol/L) × Fasting Insulin (mU/L) / 22.5. Higher HOMA values indicate decreased insulin 
sensitivity. Blood was collected by cardiac puncture at the time of euthanasia and the plasma was acid-
ethanol extracted to remove IGF binding proteins as previously described 
300
. IGF1 levels in plasma were 
measured by ELISA (R&D, Minneapolis, MN). 
 
Immunohistochemistry and histological analyses  
Histological sections were visualized with an Axio Imager.A2 bright field microscope (Zeiss; 
Thornwood, NY, USA) and a ProgRes CF Scan camera (Jenoptik; Jena, Thuringia, Germany). Following 
overnight fixation in 10% zinc formalin, closed, cross sections were embedded in paraffin for 
hematoxylin and eosin (H&E) staining. Crypt depth was measured in 20 well-oriented crypts for each 
animal using the software ProgRes Capture Pro 2.7. Splayed opened colons fixed in 4% PFA were 
cryopreserved by two subsequent overnight incubations in 10% and 30% sucrose at 4ºC. Tissues were 
embedded in Optimal Cutting Temperature compound (Sakura, Torrance, CA) and allowed to freeze on 
dry ice. Six-µm thick sections were placed on microscope slides and baked at 37ºC overnight and then at 
60ºC for 2 hours. Heat-induced epitope retrieval (HIER) was performed using HIER Buffer L pH 6.0 
(Thermo Scientific, TA-135-HBL). Slides were washed in distilled water and incubated in 3% hydrogen 
peroxide for 10 min at room temperature, and blocked with 10% normal goat serum for 1 hr. Slides were 
incubated with a cleaved caspase-3 antibody (Cell Signaling Technology, Danvers, MA) at 4ºC overnight. 
Incubation in Biotinylated Goat Anti-Rabbit antibody (Jackson Immunoresearch, West Grove, PA) was 
performed for 1 hour at room temperature. Apoptosis was assessed by quantifying cells positive for 
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cleaved caspase-3 staining in 40 well-oriented crypts for each mouse. The total number of cells per crypt 
was quantified based on hematoxylin-stained nuclei. The apoptotic indexes were determined for each 
crypt by calculating the percentage of cleaved caspase-3 positive cells relative to the total number of cells.  
 
Colon epithelial cell isolation  
Distal colon segments were placed in a solution containing 30mM EDTA/1.5mM DTT/1xPBS for 
20 minutes on ice. The tissues were transferred to a 30mM EDTA/1x PBS solution and incubated in a 
37ºC water bath for 10 minutes. Samples were shaken vigorously for 1 minute to separate the epithelium 
from the submucosal and muscularis layers and were centrifuged at 1,750 rpm for 5 minutes. Following 
two washes with 1x PBS, samples were pelleted and resuspended in RLT buffer (Qiagen, Valencia, CA) 
containing 1:100 2-mercaptoethanol (Gibco, Grand Island, NY) for RNA extraction or flash frozen for 
protein extraction. 
 
Protein extraction and Western blot 
Isolated CECs were lysed with hot Laemmli buffer, boiled, and sonicated. Protein samples were 
run on NuPAGE 4–12% Bis-Tris 1.0 mm gels (Life Technologies, Carlsbad, CA) and transferred to a 
0.45 mm pore PVDF membrane (Millipore, Billerica, MA). Membranes were blocked with Blocker 
Casein in TBS (Thermo Fisher Scientific, Waltham, MA) for 1 hour and incubated in primary antibodies 
at 4ºC overnight. Primary antibodies used were IR-β (Santa Cruz Biotechnology, Santa Cruz, CA), 
IGF1R-β, p53 and pH2AX (Cell Signaling Technologies, Danvers, MA), and β-actin (Sigma Aldrich, St. 
Louis, MO) as the loading control. Membranes were washed with 1x TBS, 0.1% Tween buffer and 
incubated in Dylight 800 goat anti-rabbit or anti-mouse IgG secondary antibodies (1:15,000, Pierce, 
ThermoScientific, Rockford, IL) at room temperature for 2 hours. Protein was visualized with an Odyssey 
CLx Infrared Imager (Version 3, LI-COR, Lincoln, NE) and band intensity was measured with ImageJ 
software (National Institutes of Health). 
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RNA isolation and high throughput real time PCR 
RNA was isolated from CECs using the RNeasy kit (Qiagen, Valencia, CA) according to 
manufacturer’s instructions. High quality RNA as determined by the 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA) was utilized for high throughput gene expression analyses using the 
BioMark HD System (Fluidigm, San Francisco, CA) as previously described
301
 based on the 
manufacturer’s protocol. An RNA pool derived from pooling equal amounts of all samples studied was 
used as the reference sample. All test mRNAs were normalized to the mRNA encoding the housekeeping 
gene hydroxymethylbilane synthase (Hmbs). TaqMan primer/probes for data presented here include 
Mm01143545_m1 (Hmbs), Mm00432051_m1 (Bax), Mm00477631_m1 (Bcl2), Mm00480750_m1 
(Perp), and Mm00438168_m1 (Cdkn1b) and were purchased from Applied Biosystems (Carlsbad, CA). 
 
Statistical analysis 
Data were collected from multiple independent experiments, each consisting of 4-8 mice. Subsets 
of mice were used for different experiments. Data were expressed as mean ± SEM. Morphological 
measurements and quantification of apoptosis, protein, and mRNA levels were analyzed by two-way 
analysis of variance (ANOVA) for main effects of diet or genotype and interactions between diet and 
genotype. Multiple comparisons were performed by Tukey’s test. All analyses were performed using 
GraphPad Prism 6 software (La Jolla, CA) and P < 0.05 was considered statistically significant. 
 
Results 
Complete genetic disruption of IGF1R or IR in IEC of VC-IGF1R
Δ/Δ
 and VC-IR
Δ/Δ
 mice 
Figure 4.2 shows a PCR gel confirming that VC-IGF1R
Δ/Δ
 and VC-IR
Δ/Δ
 mice are homozygous 
for the recombined allele of IGF1R or IR, respectively, specifically in IEC. Only floxed but intact alleles 
are observed in serosa and liver of VC mutants and IEC of WT-IGF1R
fl/fl
 and WT-IR
fl/fl
 controls.  
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IGF1R or IR loss in IEC does not impact weight gain, hyperinsulinemia, hyperglycemia, or insulin 
insensitivity resulting from long term HFD feeding  
Table 4.1 demonstrates that HFD-fed animals had increased body weight gain and fasting levels 
of blood glucose and plasma insulin compared to controls. Animals on HFD also had higher HOMA 
values, indicating decreased insulin sensitivity. There were no significant differences across genotypes in 
any of these metabolic consequences of HFD. Plasma IGF1 levels did not differ between diet groups or 
genotypes. Our data therefore demonstrate that IEC loss of IGF1R or IR had no significant effects on the 
metabolic phenotype associated with HFD feeding for 18 weeks. It should be noted that body weight gain 
in HFD-fed mice versus controls differs between the IGF1R and IR mouse colonies. However, values for 
body weight gain within control and HFD animals of the same colony were very consistent.    
  
Loss of IGF1R in CECs does not impact basal colon phenotype in obese or lean mice 
We next examined the effects of obesity and IGF1R receptor deletion on colon morphology and 
morphometry. Western immunoblot on isolated CECs confirmed complete absence of IGF1R protein in 
VC-IGF1R
∆/∆
 animals and no change in IGF1R levels during obesity (Figure 4.3A). Obese mice had 
lighter and shorter colons, and disruption of IGF1R did not impact this phenotype (Figure 4.3B-C). Colon 
crypt depth was unaffected by either obesity or loss of IGF1R (Figure 4.3D). These data suggest that 
morphology and morphometry of the colon is not altered by epithelial loss of IGF1R in lean or obese 
mice.  
 
IGF1R loss in CECs does not cause a compensatory increase in IR protein  
Since no differences were observed in gross or histological morphology of colons lacking 
epithelial IGF1R, we asked if IR protein levels were increased in response to IGF1R loss. Expression of 
IR was similar in both obese and lean WT-IGF1R
fl/fl 
mice and IGF1R loss did not significantly affect IR 
protein levels in either diet group (Figure 4.4).  
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Obesity promotes decreases in radiation-induced apoptosis of CECs and this is unaffected by 
IGF1R deletion 
We hypothesized that diet-induced obesity and hyperinsulinemia would decrease the ability of 
colonic epithelial cells to undergo apoptosis following DNA damage, and these effects would be mediated 
by IGF1R. Quantification of cleaved caspase-3 positive cells in colon crypts revealed that obese WT-
IGF1R
fl/fl
 animals had significantly lower apoptosis than their lean counterparts at 4 hours after 5 Gy 
radiation (Figure 4.5A-B). Surprisingly, no difference in the apoptotic index was observed between WT-
IGF1R
fl/fl
 and VC-IGF1R
Δ/Δ
 mice in either lean or obese groups (Figure 4.5A-B). Phospho-H2AX, a well-
established biomarker of DNA damage, was assessed by western immunoblot to verify that obesity or 
IGF1R deletion did not affect DNA damage. Levels of pH2AX were similar in all groups (Figure 4.5C-
D). Together, these findings indicate that obesity and hyperinsulinemia promote resistance of CECs to 
apoptosis after radiation-induced DNA damage and, surprisingly, IGF1R loss did not affect these results. 
 
Loss of IR in CECs does not affect basal colon phenotype and does not alter IGF1R protein 
expression in obese or lean mice  
Figure 4.6A confirms IR deletion in CECs from VC-IR
∆/∆
 mice and shows that IR protein levels 
in WT-IR
fl/fl
 animals are unaltered during obesity. Consistent with findings in the IGF1R mouse colony, 
obesity was associated with lighter and shorter colons in both WT-IR
fl/fl 
and VC-IR
∆/∆
 mice (Figure 4.6B-
C). Colon crypt depth was similar across all groups (Figure 4.6D) and neither obesity nor IR loss affected 
IGF1R protein levels (Figure 4.7). These data indicate that loss of IR in CECs has no detectable effects on 
colon morphology or morphometry and does not lead to a compensatory increase in IGF1R protein.  
 
IR loss promotes apoptosis of genetically damaged CECs in lean and obese animals 
We next examined if the anti-apoptotic effects of obesity or hyperinsulinemia on CECs with 
DNA damage were mediated by IR rather than IGF1R. Obese WT-IR
fl/fl
 mice had lower levels of 
apoptosis than lean WT-IR
fl/fl
 mice (Figure 4.8A-B), consistent with findings in the IGF1R group. 
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Interestingly, lean VC-IR
Δ/Δ
 mice had significantly higher levels of apoptosis than lean WT-IR
fl/fl
 mice, 
providing evidence that IR loss increases CEC apoptosis. In the obese group, VC-IR
Δ/Δ
 mice also had 
higher apoptosis than WT-IR
fl/fl
 animals, further indicating anti-apoptotic roles of IR. However, apoptosis 
levels in obese VC-IR
Δ/Δ 
mice remained significantly lower than in lean VC-IR
Δ/Δ 
mice (Figure 4.8A-B). 
Levels of the DNA damage marker pH2AX were not affected by diet or genotype (Figure 4.8C-D). 
Overall, our results show that disruption of IR promotes apoptosis of genetically damaged CECs in both 
lean and obese mice. However, obesity is still associated with reductions in apoptosis in mice lacking IR.   
 
Obesity and IR loss impact protein expression of p53 and mRNA levels of Perp and Cdkn1b in 
genetically damaged CECs 
We next sought to investigate potential molecular mediators influenced by obesity and IR that 
may contribute to resistance of CECs to apoptosis after DNA damage. CECs were isolated from WT-IR
fl/fl
 
and VC-IR
Δ/Δ
 mice and levels of pro-apoptotic and anti-apoptotic regulators were assessed. We first 
examined p53, a key sensor of DNA damage that is a required mediator of apoptosis in the intestinal 
crypts within the initial hours following radiation 
231,238
. At 4 hours after 5 Gy radiation, we observed a 
non-significant trend (P = 0.08) for reduced p53 in CECs of obese versus lean WT-IR
fl/fl
 animals (Figure 
4.9A-B). Both lean and obese VC-IR
∆/∆
 mice had significantly increased p53 protein levels compared 
with their WT-IR
fl/fl
 counterparts (Figure 4.9A-B). Next, we performed high throughput qRT-PCR on 
regulators of apoptosis and cell cycle progression. We found no changes in mRNA levels of pro-apoptotic 
Bax or anti-apoptotic Bcl2 in obese versus lean mice across genotypes (Figure 4.9C-D). However, mRNA 
levels of the pro-apoptotic Perp (p53 apoptosis effector related to PMP-22) and the tumor suppressor 
Cdkn1b (which encodes for p27) were significantly down-regulated in CECs of obese WT-IR
fl/fl 
and VC-
IR
∆/∆
 mice versus lean mice of the same genotype (Figure 4.9E-F). Both Perp and Cdkn1b mRNAs were 
significantly higher in lean VC-IR
∆/∆
 mice than in lean WT-IR
fl/fl
 controls. These data show a potential 
contribution of p53 and p53-regulated genes to the differential apoptosis response of CECs during obesity 
and IR deletion. 
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Discussion 
This study aimed to investigate the effects of obesity on apoptosis of colonic epithelial cells 
(CECs) after radiation-induced DNA damage and test our original hypothesis that IGF1R loss would have 
an impact on these effects. We used a mouse model of HFD-induced obesity and hyperinsulinemia with 
genetic deletion of IGF1R specifically in intestinal epithelial cells (IEC). We found that 4 hours after 
DNA damage induced by 5 Gy radiation, obesity led to reduced CEC apoptosis and this was unaffected 
by IGF1R loss. Given this surprising result, we next studied mice with IEC-specific deletion of IR to test 
if IR contributed to the anti-apoptotic effects of obesity. We found that IR loss significantly increased 
apoptosis of genetically damaged CECs in both lean and obese mice but did not prevent the reduction in 
apoptosis in obese animals. Together, our studies on two independent mouse colonies showed that obesity 
and hyperinsulinemia decrease apoptosis of CECs after radiation-induced DNA damage. Furthermore, we 
provide novel and unexpected evidence that loss of IR, but not IGF1R, increases apoptosis of genetically 
damaged CECs in lean or obese mice, indicating novel anti-apoptotic roles of IR in the colon.   
A large body of clinical data strongly links obesity, hyperinsulinemia, insulin therapies, and 
diabetes to CRC risk 
155,187,285,286,294,302
, and considerable interest in the role of the insulin/IGF system in 
mediating this risk has emerged. Due to the structural similarities and overlapping functions of IGF1R 
and IR, defining their individual roles in growth and cell death in different tissues has been challenging. 
We therefore generated mice with IEC-specific disruption of IGF1R or IR in the intestinal epithelium. 
The colons of these mice show no obvious basal phenotype, as demonstrated by the lack of effects on 
colon length, weight and crypt depth with loss of either receptor. These mouse models were first used to 
evaluate the early effects of obesity on apoptosis of genetically damaged cells in normal colonic 
epithelium which may reflect an important mechanism to remove cells that could harbor potentially 
oncogenic mutations. Our findings in two independent experiments on two independent colonies of mice 
with diet-induced obesity and hyperinsulinemia provide, to our knowledge, new, direct evidence that 
obesity and hyperinsulinemia are associated with reduced apoptosis of genetically damaged cells. This 
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preclinical evidence supports our findings in humans linking increased plasma insulin to reduced 
apoptosis in normal rectal mucosa, which in fact predicted risk of colorectal polyps 
155,165
.  
The role of IR in the gut epithelium has been largely ignored, and significantly more attention has 
been focused on IGF1R due to its known role in growth and cancer 
119,180,292. Circulating “free” IGF1, 
which increases during elevated plasma insulin due to inhibition of hepatic production of IGFBPs 
153
, has 
been associated with normal and aberrant growth of colon 
112,303,304
. In line with this concept, IGF1R has 
been considered a critical mediator of the proliferative and anti-apoptotic effects of elevated insulin or 
IGF1. Our findings that loss of IGF1R did not impact radiation-induced apoptosis of CECs are therefore 
unexpected and may suggest that, in the colon, IGF1R is not essential for anti-apoptotic actions. Loss of 
IR, however, led to a dramatic increase in apoptosis of genetically damaged CECs. A direct role for IR in 
apoptosis has been previously described in primary hepatocypes of newborn mice and in mouse embryo 
fibroblasts 
305,306
. Here, we provide the first direct evidence that IR exerts anti-apoptotic actions in the 
adult colon epithelium.   
Our studies indicated that the increase in apoptosis associated with IR deletion occurred 
regardless of whether animals were lean or obese, since apoptosis levels in obese VC-IR
Δ/Δ
 mice still 
remained lower than in lean VC-IR
Δ/Δ
 littermates. This suggests that factors other than insulin signaling 
may mediate the anti-apoptotic effects of obesity. When we examined protein expression in CECs of WT-
IR
fl/fl 
animals, we found a non-significant, consistent decrease in p53 with obesity. Relative to WT-IR
fl/fl
 
mice, loss of IR led to a slight but significant increase in p53 protein in both obese and lean groups. These 
small differences in protein expression may reflect the fact that the apoptosis phenotype we observed 
histologically is restricted to a few cells per crypt (2-4 cells in lean mice and 1-2 cells in obese mice) and 
examining total CECs may therefore mask any changes in protein levels in crypt cells undergoing 
apoptosis. A study on mouse embryonic fibroblasts showed that, after DNA damage, IGF1 treatment 
induced p53 protein degradation via the MAPK pathway 
307
. However, whether these effects were 
mediated by IGF1R or IR-A was not investigated. It could therefore be speculated that in the colon 
epithelium, where IR-A is the predominant isoform 
294
, increased protein levels of p53 in VC-IR
Δ/Δ
 mice 
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may result from loss of IR-A signaling. Analyses of CEC mRNA revealed that Perp and Cdkn1b were 
increased in lean mice lacking IR and decreased in obese mice regardless of genotype. Perp is 
transcriptionally induced by p53 in normal and cancer cells specifically during apoptosis 
308-310
. Cdkn1b 
encodes the tumor suppressor p27, which promotes cell cycle arrest at G1 by inhibiting cyclin-dependent 
kinases, is down-regulated in tumors from p53 null mice, and can be up-regulated by p53 to protect 
normal IEC from the cytotoxic effects of chemotherapy 
311-313
. These data showing changes in Perp and 
Cdkn1b mRNA levels in genetically damaged CECs of obese and lean VC-IR
Δ/Δ
 mice are consistent with 
the anti-apoptotic effects of obesity and IR observed by histology. We note that in mice lacking IR, Perp 
and Cdkn1b mRNAs are significantly decreased with obesity, but p53 protein is not. This discrepancy 
could be due to the fact that the western blot experiments used whole cell lysates and therefore do not 
provide information on p53 nuclear translocation, which is required to activate gene transcription after 
DNA damage. Alternatively, elevated p53 may reflect a mechanism by which loss of IR increases 
apoptosis while reduced Perp and Cdkn1b mRNAs reflect other pathways that maintain apoptosis at low 
levels during obesity. This would cause obese VC-IR
Δ/Δ
 mice to have higher apoptosis than obese WT-
IR
fl/fl
 mice but lower apoptosis than their lean VC-IR
Δ/Δ
 counterparts.  
Our study is to our knowledge the first to directly show that obesity and hyperinsulinemia 
promote resistance of CECs to apoptosis after DNA damage. Furthermore, we provide novel evidence 
that IR and not IGF1R normally protects genetically damaged CECs from apoptosis. Overall, our work 
suggests that: (i) the mediators of obesity-associated reductions in apoptosis should be further explored as 
they may represent a potential early mechanism driving colon tumorigenesis and (ii) more attention 
should be given to the physiological roles of IR in cell death and survival in the colon crypts to better 
understand the mechanisms underlying normal or aberrant colon growth.       
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Figures and Tables 
 
 
 
Figure 4.1: Colon tissue harvest. 
First group of animals: the entire colon was splayed opened and fixed in 4% paraformaldehyde (PFA) for 
histological assessment of apoptosis. Second group of mice: one closed piece of proximal and one closed 
piece of distal colon (~1cm each) were fixed in 10% Zn formalin to confirm apoptosis scoring, and 3-4 
cm of the distal colon were splayed opened and used for epithelial cell isolation. 
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Figure 4.2: Intestinal epithelial cell (IEC)-specific villin-Cre mediated recombination of Igf1r and 
Insr genes in VC-IGF1R
Δ/Δ
 and VC-IR
Δ/Δ
 mice, respectively. 
PCR gels for floxed regions in exon 3 of the Igf1r gene and exon 4 of the Insr gene in IEC, intestinal 
serosa, and liver DNA from (A) WT-IGF1R
fl/fl
 and VC-IGF1R
∆/∆
 mice and (B) WT-IR
fl/fl
 and VC-IR
∆/∆
 
mice. Only mice carrying the villin-Cre recombinase are homozygous for the recombined (recomb.) 
alleles specifically in IEC and not in other tissues. 
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Table 4.1: IEC-specific loss of IGF1R or IR does not affect obesity-associated changes in body 
weight, blood glucose, plasma insulin, and insulin sensitivity. 
 WT-IGF1R
fl/fl
 VC-IGF1R
Δ/Δ
  WT-IR
fl/fl
 VC-IR
Δ/Δ
 
 
CTL HFD CTL HFD 
 
CTL HFD CTL HFD 
Body weight 
gain (%) 
39.5  
±10.0 
101.6 
±4.2
a
 
31.2  
±8.1 
93.9 
±10.5
a
  
24.9  
±1.7 
70.4 
±6.2
a
 
25.7  
±3.2 
71.0 
±5.8
a
 
Fasting blood 
glucose (mg/dl) 
127.1 
±11.3 
164.6 
±16.4 
127.6 
±17.3 
167.1 
±13.8  
108.2 
±2.3 
151.8 
±11.3
a
 
108.7 
±8.8 
167.5 
±10.4
a
 
Fasting plasma 
insulin (μg/l) 
0.2  
±0.03 
1.1 
±0.2
a
 
0.3 
±0.1 
1.3 
±0.3
a
  
0.27 
±0.03 
1.16 
±0.23
a
 
0.27 
±0.07 
1.14 
±0.19
a
 
HOMA 
2.3  
±0.4 
13.9 
±3.0
a
 
2.5 
±0.9 
15.0 
±3.89
a
  
2.0 
±0.2 
12.6 
±2.7
a
 
2.2 
±0.8 
15.4 
±2.8
a
 
Plasma 
IGF1(ng/ml) 
31.8  
±11.2  
46.7 
±3.8 
40.8 
±4.0 
37.1 
±6.6  
49.3 
±2.6 
52.2 
±4.5   
49.7 
±3.3  
51.2 
±2.2 
a: P < 0.05 vs. CTL same genotype  
Two-way ANOVA, Tukey’s multiple comparisons test 
n ≥ 5  
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Figure 4.3: Obesity does not affect IGF1R protein expression in CECs of WT-IGF1R
fl/fl
 mice and 
IGF1R loss does not alter colon weight, length, or crypt depth in lean or obese mice. 
(A) Representative western blot for IGF1R protein in isolated CECs of lean and obese WT-IGF1R
fl/fl
 and 
VC-IGF1R
∆/∆
 mice. B-D: Measurements of colon (B) weight, (C) length and (D) crypt depth in each 
group. Western blot is representative of n ≥ 3. Data in bar graphs represent mean ± SEM (n ≥ 4). a: P < 
0.05 versus lean same genotype, n.s.: no significance, two-way ANOVA with Tukey’s multiple 
comparisons test.  
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Figure 4.4: Neither obesity nor IGF1R deletion impact IR protein levels in CECs. 
(A) Representative western blot showing IR protein in isolated CECs of lean and obese WT-IGF1R
fl/fl
 and 
VC-IGF1R
∆/∆
 animals. (B) Quantification of IR protein levels relative to β-actin expressed as mean ± 
SEM (n ≥ 3), n.s.: no significance, two-way ANOVA. 
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Figure 4.5: Reduced apoptosis of genetically damaged CECs in obese mice with intact IGF1R or 
IGF1R deletion and no changes in levels of the DNA damage marker pH2AX across groups. 
(A) Representative images showing cleaved caspase-3 staining in distal colon of lean and obese WT-
IGF1R
fl/fl
 and VC-IGF1R
∆/∆
 mice (40x objective, scale bar = 50 μm). (B) Apoptotic index calculated 
using the formula: number of cleaved caspase-3 positive cells/total number of cells x 100. Data represent 
mean ± SEM (n ≥ 5). (C) Representative western blot showing pH2AX protein in isolated CECs of lean 
and obese WT-IGF1R
fl/fl
 and VC-IGF1R
∆/∆
 animals. (D) Quantification of pH2AX levels relative to β-
actin expressed as mean ± SEM (n ≥ 3). a: P < 0.05 versus lean same genotype, n.s.: no significance, two-
way ANOVA with Tukey’s multiple comparisons test.  
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Figure 4.6: Obesity does not affect IR protein expression in CECs of WT-IR
fl/fl
 mice and IR deletion 
does not affect measures of colon growth. 
(A) Representative western blot for IR in isolated CECs of lean and obese WT-IR
fl/fl
 and VC-IR
∆/∆
 mice. 
B-D: Measurements of colon (B) weight, (C) length and (D) crypt depth in each group.  Western blot is 
representative of n = 4. Quantitative data were expressed as mean ± SEM (n ≥ 4). a: P < 0.05 versus lean 
same genotype, n.s.: no significance, two-way ANOVA with Tukey’s multiple comparisons test.  
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Figure 4.7: IR loss does not impact IGF1R protein levels in CECs of lean or obese mice. 
(A) Representative western blot showing IGF1R protein levels in isolated CECs of lean and obese WT-
IR
fl/fl
 and VC-IR
∆/∆
 animals. (B) Quantification of IGF1R protein relative to β-actin expressed as mean ± 
SEM (n = 4), n.s.: no significance, two-way ANOVA with Tukey’s multiple comparisons test.  
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Figure 4.8: IR loss increases apoptosis of genetically damaged CECs in lean and obese mice and 
levels of pH2AX do no change across groups. 
(A) Representative images showing cleaved caspase-3 staining in distal colon of lean and obese WT-IR
fl/fl
 
and VC-IR
∆/∆
 mice (40x objective, scale bar = 50 μm). (B) Apoptotic index calculated using the formula: 
number of cleaved caspase-3 positive cells/total number of cells x 100. Data were expressed as mean ± 
SEM (n ≥ 5). (C) Representative western blot showing pH2AX protein in isolated CECs of lean and obese 
WT-IR
fl/fl
 and VC-IR
∆/∆
 animals. (D) Quantification of pH2AX expression relative to β-actin expressed as 
mean ± SEM (n = 4). a: P < 0.05 versus lean same genotype, b: P < 0.05 versus WT same diet group, 
two-way ANOVA with Tukey’s multiple comparisons test. 
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Figure 4.9: Obesity and IR deletion alter levels of p53 protein and p53-regulated mRNAs. 
(A) Western blot showing p53 protein expression in isolated CECs of lean and obese WT-IR
fl/fl
 and VC-
IR
∆/∆
 mice. (B) Quantification of p53 protein levels relative to β-Actin by densitometry. C-F: mRNA 
levels of (C) anti-apoptotic Bcl-2, (D) pro-apoptotic Bax, (E) pro-apoptotic Perp, and (F) tumor 
suppressor Cdkn1b. Bar graphs in panels B-F show fold change versus lean WT-IR
fl/fl
 control. Data were 
expressed as mean ± SEM (n = 4 in duplicates for protein data and n ≥ 4 for mRNA data). a: P < 0.05 
versus lean same genotype, b: P < 0.05 versus WT same diet group, two-way ANOVA with Tukey’s 
multiple comparisons test. 
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CHAPTER 5: NOVEL ROLES FOR IR IN CRC RISK AND COLON APOPTOSIS: 
SIGNIFICANCE AND FUTURE AREAS OF INVESTIGATION 
 
 The first evidence for presence of insulin receptors in the mammalian colon was reported in 
1985
314
. However, the function of IR in the intestine has been largely ignored, probably because the 
intestine does not rely on insulin for carbohydrate metabolism 
315
. Thus, IR has been primarily studied in 
‘traditional’ targets of the metabolic actions of insulin such as skeletal muscle, adipose tissue, and liver, 
as well as in the insulin-producing β-cells of the pancreas 273,316-318. In contrast, significant attention has 
been given to intestinal IGF1R since it is generally considered the major mediator of the effects of IGF1, 
IGF2, or elevated insulin on growth, anti-apoptosis, regeneration, and cancer 
78,112,120,129,130,203,235
.  
However, it is only recently that we and others have been able to generate mouse models with genetic 
deletion of IR or IGF1R in intestinal epithelial cells to more directly define the roles of these two related 
receptors.  
In 1999, Frasca et al. provided evidence for increased IR-A expression in human colon cancer 
tissues 
90
. Additionally, human studies have found positive correlations between elevated plasma insulin 
and risk of colorectal adenomas and cancer 
155,186,187
. These lines of evidence and the fact that both IGF1 
and insulin can signal through either IGF1R or IR prompted us to investigate the specific roles of each 
receptor in the early stages of colorectal carcinogenesis. Distinguishing functional roles of IGF1R and IR 
in vivo has been a challenge due to their structural and functional similarities. The mouse models with 
IEC-specific deletion of IGF1R or IR used in our studies are therefore powerful tools to directly define in 
vivo contributions of each receptor in distinct physiological and pathophysiological contexts. The fact that 
the IEC-IGF1R and IEC-IR deletion mutants had no detectable basal phenotype permitted us to challenge 
them with damage or tumor inducing stimuli to define their roles in disease-relevant situations.  
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This dissertation aimed to first define the expression levels of IGF1R, IR, and IR isoforms in the 
normal mucosa of patients with or without colorectal adenomas, in order to establish whether mRNA 
levels of these receptors could predict adenoma risk, particularly during elevated plasma insulin. In the 
second portion of this dissertation, IEC-specific IR knockout mice treated with AOM-DSS were used to 
determine the impact of IR loss on tumorigenesis. The third part of this work examined DNA damage, the 
earliest step in tumor initiation. The goal was to evaluate the effects of loss of IGF1R or IR on apoptosis 
of genetically damaged colon epithelial cells (CECs) during diet-induced obesity or hyperinsulinemia. 
This final chapter will discuss the overall findings, future directions for research, and the clinical 
significance of this work.  
 
Hyperinsulinemia and colorectal adenoma risk 
IR-A and IR-B isoforms or IGF1R as predictive biomarkers 
 The human study in the first part of this dissertation reported two main novel findings (Figure 
5.1): (i) IGF1R mRNA is modestly but significantly down-regulated in the normal mucosa of adenoma 
cases compared with adenoma-free controls and (ii) increased IR-A:IR-B ratio is associated with 
increased risk of adenomas in patients in the upper half of plasma insulin. The latter appeared to be due to 
reduced IR-B and maintained IR-A expression, as observed semi-quantitatively based on RT-PCR. These 
results provide evidence that IR-B protects against early stage colon tumorigenesis in humans with 
elevated plasma insulin. 
 The findings that low IGF1R mRNA predicted adenoma risk were unexpected and may suggest 
that overexpression of IGF1R in carcinogenesis may become more relevant at later stages in the 
adenoma-cancer sequence. Since IGF1 is known to negatively feedback on IGF1R receptor expression in 
a number of cell types and its production is elevated in colon adenomas in preclinical models 
97,319-321
, it is 
possible that local IGF1 secreted by adenomas act in a paracrine manner on the surrounding normal 
mucosa to down-regulate IGF1R in cases. Increased circulating levels of free IGF1 could also contribute 
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to this down-regulation, but plasma IGF1 was not measured in this study and prior studies did not report 
elevated plasma IGF1 in adenoma patients 
155
. We considered that high insulin may drive reduced IGF1R 
but IGF1R levels were elevated regardless of plasma insulin 
269
. Thus the mechanism and significance of 
low IGF1R mRNA in adenoma cases remains to be further evaluated.  
 Interestingly, IR-A:IR-B ratios were increased in cases versus controls with high plasma insulin. 
This relationship was strengthened by logistic regression analyses showing that as IR-A:IR-B ratios 
increased, patients with elevated insulin were more likely to have adenomas than patients with low 
insulin. Rather than increased IR-A, these alterations in IR-A:IR-B ratios seemed to be dictated by 
reductions in IR-B. This suggests that insulin-induced regulation of IR isoform expression may be 
relevant to the mechanisms underlying adenoma risk. Total IR mRNA did not differ between cases and 
controls, suggesting that the relative amounts of IR isoforms should be the focus of future studies 
examining IR. 
 One question that remained unanswered by this study is whether adenomas express higher IR-
A:IR-B ratios during normal or high plasma insulin. This is unknown in humans, but our recent 
publication showed increased IR-A:IR-B ratio in adenomas from Apc
Min/+
 mice due to reduced IR-B 
97
. 
Consistent with these findings, preliminary data obtained during this work showed that, compared with 
normal colon epithelium from untreated mice, adenomas from AOM-DSS mice had increased IR-A:IR-B 
ratio resulting from decreased IR-B (Figure 5.2).  
 Together, this work leads to a new area in colorectal cancer prevention research that should be 
further explored to define if altered IR-A, IR-B, or IGF1R expression in normal colon biopsies better 
predict colorectal adenoma risk, particularly in patients with hyperinsulinemia or insulin resistance. Thus, 
identification of those patients at greatest risk for CRC who would benefit from more frequent 
colonoscopy-based surveillance could help decrease CRC morbidity and mortality. 
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Regulation of IR isoform pre-mRNA splicing 
There is currently limited information on the mechanisms controlling pre-mRNA splicing of IR 
isoforms. It is well established, however, that CUG RNA binding protein 1 (CUGBP1), muscleblind 
proteins (MBNL), and serine/arginine-rich splicing factors (SRSFs) regulate IR alternative splicing in 
muscle (Figure 5.3), and more recently we found that they also play a role in the intestine 
97
. Most of the 
evidence for roles of these proteins in IR isoform expression resulted from studies on myotonic dystrophy 
(DM), an autosomal dominant muscle disease that is characterized by expanded CUG repeats in the RNA 
encoding DM protein kinase (DMPK) 
322
. Patients show insulin resistance in skeletal muscle and this has 
been associated with increases in CUGBP1 that favor IR-A expression 
322
. In contrast, MBNL1 and 
MBNL2 favor generation of IR-B (Figure 5.3), and this is inhibited by CUGBP1 
323
. In vitro studies 
demonstrated that MBNL1 and SRSF3 promote exon 11 inclusion and expression of IR-B by binding to 
intronic and exonic splicing enhancers, respectively 
324,325
. CUGBP1 promotes exon 11 exclusion and 
expression of IR-A by binding to intronic and exonic splicing silencers 
325
. Consistent with this evidence, 
our recent work showed that in differentiated Caco2 colorectal cancer cells, which express higher IR-B 
than in the undifferentiated state, CUGBP1 transcript levels were decreased and MBNL2 levels were 
increased 
97
. In contrast, in colon and small intestinal adenomas from Apc
Min/+
 mice where IR-A 
predominates, MBNL2 expression was reduced 
97
. Studies on human liver recently demonstrated that 
compared with normal hepatocytes where IR-B is by far the predominant isoform, hepatocellular 
carcinomas showed increased relative expression of IR-A, which correlated with increased CUGBP1 
levels 
276
. Interestingly, CUGBP1-induced expression of IR-A was regulated by the oncogenic 
EGFR/MAPK pathway 
276
.     
Expression patterns of these splicing factors in human intestine have not been examined. 
Measuring the levels of splicing factor mRNAs in the human biopsies used in our studies could provide 
insight into mechanisms by which high plasma insulin up-regulates IR-A:IR-B ratio to promote adenoma 
risk. In biopsies from cases with elevated insulin, which show increased IR-A:IR-B ratio due to reduced 
IR-B, we would anticipate decreased MNLBs and increased or maintained CUGBP1. More direct 
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mechanistic studies on whether elevated insulin itself or insulin resistance affects IR isoform splicing 
could be addressed in vivo or in vitro. Using the conditional reprogramming method described in Chapter 
3, cells from normal colon mucosa of patients with or without adenomas, or human adenoma cells, if 
available, could be plated on feeders or matrigel to evaluate their proliferative capacity and the relative 
abundance of IR isoforms with or without insulin treatment. Knockdown of IR by shRNA and re-
expression of IR-A or IR-B would test whether insulin-mediated cell growth and survival are enhanced by 
IR-A or attenuated by IR-B. Alternatively, splicing factors could be modulated by transfecting cells with 
lentiviral constructs expressing shRNAs for MBNL2 and CUGBP1, which are available in our laboratory. 
If increased IR-A levels relative to IR-B prove to be a driver of adenoma cell growth and anti-apoptosis, 
treatment with EGFR inhibitors to reduce IR-A expression and favor IR-B would be of interest. EGFR 
inhibitors are currently used in combination with chemotherapy for the treatment of CRC
32
, and an effect 
on IR splicing in colonocytes or cells from adenomas would provide insight into mechanisms by which 
EGFR inhibitors may prevent or treat CRC. Additionally, given the role of EGFR in IR splicing in liver
276
 
and our previous studies demonstrating synergistic proliferative effects of EGF and IGF in intestinal 
epithelial cells 
326
, it would be of interest to test EGF and IGF in combination to assess if they more 
potently down-regulate IR-B or affect splicing factors.      
 
Mechanisms of decreased colon epithelial cell apoptosis during obesity/hyperinsulinemia 
 Chapter 4 of this dissertation described the impact of obesity and IR on apoptosis of CECs after 
radiation-induced DNA damage. We provided evidence that obesity and hyperinsulinemia were 
associated with decreased apoptosis in the colonic crypts and, importantly, this was confirmed in two 
independent mouse colonies. This supports a previous human study where elevated plasma insulin 
correlated with decreased apoptosis in normal rectal mucosa 
155
. A somewhat similar finding in mice was 
reported after 5 injections of AOM, where AOM-induced apoptosis was decreased in animals that had 
been on high fat diet (HFD) for 7 or 15 weeks before the last AOM dose 
327
. However, mice did not 
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appear to be obese or hyperinsulinemic, and the authors attributed reduced AOM-induced apoptosis to the 
lower per-body-weight dose of AOM that the obese mice had received 
327
.  
We originally hypothesized that the growth-promoting IGF1R would be required for any anti-
apoptotic effects of obesity/hyperinsulinemia. Unexpectedly, genetic deletion of IGF1R in CECs did not 
impact apoptosis in lean or obese mice. We then asked if IR played a role in mediating these effects. 
Although IR loss did increase apoptosis in both lean and obese animals, which was an exciting and novel 
finding, apoptosis remained lower in obese mice relative to lean mice lacking IR. These data imply that 
IR is not required for the reductions in apoptosis associated with obesity/hyperinsulinemia. The current 
section will discuss potential mechanisms that may explain lower radiation-induced apoptosis in obese 
versus lean mice whether or not IR is present, as summarized in Figure 5.4. 
 
IGF1R hyperactivation due to IR deletion 
One hypothesis we could formulate is that in the absence of IR, elevated insulin as occurs in our 
obese model exerts anti-apoptotic signals through the remaining IGF1R (Figure 5.4). Although IGF1R 
protein levels did not increase to compensate for IR loss, we cannot rule out a compensatory mechanism 
by increased IGF1R activation rather than expression. This could be possible given that IR deletion 
enhanced tumor cell growth and increased IGF1-induced AKT activation as suggested in our studies in 
Chapter 3. Evaluating phosphorylation of IGF1R or downstream mediators in the intestinal epithelium in 
vivo is difficult because signaling pathways are activated during handling and harvest of the intestine and 
almost certainly affected by epithelial cell isolation methods. In vitro studies in conditionally 
reprogrammed CECs isolated from WT-IR
fl/fl
 and VC-IR
∆/∆
 provide an alternate approach. 
 
AMP-activated protein kinase  
 AMP-activated protein kinase (AMPK) is a key metabolic sensor that is activated in response to 
increased intracellular AMP/ATP ratios, when energy in the cell is low 
328
. AMPK activation induces 
energy-producing processes such as glucose uptake, glycolysis, and fatty acid oxidation, and inhibits 
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energy-consuming processes such as gluconeogenesis, lipogenesis, and glycogen synthesis as well as, in 
some organs, cell proliferation 
201,329
. It is well known that AMPK action is decreased in situations of 
insulin resistance and obesity 
330
, and activation of AMPK by drugs such as metformin improves glucose 
uptake in muscle and inhibits hepatic gluconeogenesis during type 2 diabetes 
200
.  
Moreover, a role for AMPK in modulating the DNA damage response has been reported 
329
. In 
vitro studies suggest that AMPK activation sensitizes cancer cells to chemotherapy or radiation by 
blocking cell cycle progression via p53, p21, and p27 induction as well as inhibiting the pro-survival 
mammalian target of rapamycin (mTOR) pathway 
329
. Therefore, AMPK has been implicated in cell cycle 
arrest and apoptosis following DNA damage 
329
. These mechanisms should be examined in our studies, as 
AMPK activity in the intestine could be reduced as a consequence of obesity and insulin resistance, 
thereby contributing to decreased radiation-induced apoptosis of CECs in obese mice (Figure 5.4). It 
should be noted that AMPK activates the cell cycle inhibitor p27, and we found p27 mRNA to be down-
regulated in CECs from obese mice. However, no significant changes were observed in markers of S-
phase (5-ethynyl-2'-deoxyuridine, EdU) or M-phase (phospho-histone 3, pH3) in obese mice (Figure 5.5). 
The role of AMPK in the colon has not been well explored, but a study reported that in mice fed a high-
energy diet, AMPK activation by metformin decreased tumor growth of xenografts derived from a CRC 
cell line 
279
. This was associated with decreased phosphorylation of AKT signaling and increased 
expression of apoptosis markers in tumors cells 
279
. Moreover, activation of AMPK was associated with 
reductions in AOM-induced ACF in the db/db mouse model of obesity and diabetes treated with the anti-
oxidant curcumin or the cholesterol-lowering drug pitavastatin 
331,332
. Therefore, metformin treatment 
prior to radiation may sensitize CECs of obese animals to radiation-induced apoptosis, as was previously 
shown in cancer cells 
200
. If in obese mice metformin-induced AMPK activation increased apoptosis of 
genetically damaged CECs back to levels observed in lean mice, this would be exciting mechanistic 
evidence for roles of impaired AMPK action. Furthermore, these experiments would support a potential 
mechanism for the anti-tumor effects of metformin, specifically, an effect to prevent genetically damaged 
cells from expanding and forming pre-neoplastic lesions in the colon.  
   
98 
 
Microbiota  
The gut microbiota is an important regulator of energy balance and a key factor contributing to 
development of obesity, as demonstrated by the fact that germ-free (GF) mice do not become obese after 
HFD feeding 
71
. An increase in the proportion of Firmicutes relative to Bacteroidetes phyla during obesity 
has been well documented in both mice and humans 
69,333
.  Firmicutes consist mostly of gram-positive 
bacteria, while Bacteroidetes belong to the category of gram-negative bacteria 
334
. Gram-positive bacteria 
are known to produce the short-chain fatty acid butyrate, which can prevent apoptosis of colonocytes 
335,336
. Therefore, a shift to increased abundance of butyrate-producing bacteria as a result of obesity could 
contribute to reduced colonocyte apoptosis after genetic damage, independently of IR (Figure 5.4). 
Butyrate levels in the feces could be measured to determine if they differ between lean and obese animals. 
If a shift towards butyrate-producing bacteria correlated with decreased apoptosis during obesity, the 
microbiota could be manipulated in obese mice so that the Firmicutes-to-Bacteroidetes ratio is restored to 
values observed in lean mice prior to radiation. Monitoring butyrate in the feces would provide 
information on the time point at which butyrate levels are comparable between the two groups, and 
animals would then be irradiated to evaluate effects on apoptosis. We would predict that normalization of 
the Firmicutes-to-Bacteroidetes ratios would increase levels of radiation-induced apoptosis in obese mice 
to levels observed in lean mice. An alternate approach would be to colonize germ-free mice with 
microbiota from lean or obese mice before or after irradiation and test if the microbiota from obese mice 
is sufficient to confer reduced apoptosis.  
 
Linking the anti-tumorigenic and anti-apoptotic roles of IR in the colon 
 The work described in our AOM-DSS study in Chapter 3 provided novel evidence that IR 
protects against colon tumorigenesis by enhancing the oncogenic actions of IGF1R. In line with this 
evidence, it would be reasonable to hypothesize that IGF1R and not IR is the main mediator of CEC 
survival after genetic damage, which may favor initiation of colonic pre-cancerous lesions. Surprisingly, 
IR but not IGF1R deletion was found to result in higher apoptosis, as shown in Chapter 4, suggesting 
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anti-apoptotic roles of IR at least in the context of early radiation-induced apoptosis. The counterintuitive 
results that IR loss in CECs leads to enhanced tumorigenesis in the AOM-DSS model but enhanced 
apoptosis in a genetic damage model raise two important questions for future consideration: (i) what is the 
significance of apoptosis in the colon epithelium after radiation-induced DNA damage with respect to 
tumor development and (ii) what is the role of colon epithelial IGF1R during DNA damage and 
tumorigenesis and does this depend on whether IR expression or signaling is intact? These questions will 
be addressed below. 
 
Apoptosis: A beneficial or detrimental response to radiation-induced DNA damage? 
 One interpretation of enhanced apoptosis of genetically damaged CECs due to IR loss is that IR 
has anti-apoptotic roles that may favor tumorigenesis by allowing genetically damaged cells to escape 
apoptosis. This interpretation assumes that apoptosis is a beneficial response to DNA damage that reduces 
tumor risk. This is based on the well-established concept that apoptosis occurs to eradicate genetically 
damaged cells that accumulate mutations or chromosomal aberrations and could survive and expand to 
initiate cancer 
288,289
. However, our observations indicate that IR normally limits radiation-induced 
apoptosis and limits tumor development at least in the AOM-DSS model. Therefore, these findings 
suggest that apoptosis may have no role in the AOM-DSS model or, alternatively, increased apoptosis in 
the absence of IR might have unfavorable consequences for tumorigenesis which may be dependent on 
inflammation. Massive DNA damage and apoptosis can have adverse effects on the regenerative capacity 
of stem cells or progenitors, thus compromising epithelial renewal 
289
. Increased apoptosis can disrupt the 
integrity of the epithelial barrier, allowing penetration of luminal bacteria into the mucosa which triggers 
an inflammatory response (Figure 5.6) 
337-339
. It is well known that inflammation causes DNA damage, 
but emerging evidence has led to a new concept that DNA damage can in fact trigger inflammation 
340
. 
This process, which is reviewed in detail by McCool and Miyamoto, 2012, appears to involve activation 
of NF-κB by ATM-induced phosphorylation of NEMO (NF-κB essential modulator) 341-343. Therefore, IR 
loss could favor tumor initiation by increasing apoptosis and secondarily exacerbating inflammation after 
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DNA damage (Figure 5.6). We have in hand NF-κBEGFP mice, which express EGFP upon NF-κB 
activation 
67
. Generating NF-κBEGFP mice with IEC-specific IR deletion (NF-κBEGFP/VC-IRΔ/Δ) would 
allow us to test if loss of IR favors enhanced NF-κB activation as a biomarker of inflammation in the 
colon epithelium after DNA damage. Evaluating inflammatory markers in VC-IR
∆/∆
 CECs would provide 
information on the extent of inflammation resulting from DNA damage in the absence of IR. Moreover, 
additional time points and higher radiation doses would allow us to assess if IR loss affects later waves of 
apoptosis that follow the initial wave at ~4 hours after radiation or impairs epithelial regeneration. 
Whether loss of IR in the colon epithelium affects barrier function or permeability is unknown, but our 
previous in vitro findings provided evidence that IR-B promotes barrier function in differentiated Caco2 
cells 
97
. Assessing colon epithelial permeability in WT-IR
fl/fl
 versus VC-IR
Δ/Δ
 mice would be possible by 
rectal administration of the fluorescent probe FITC-dextran 
344
. We would predict that VC-IR
Δ/Δ
 animals 
would have elevated levels of FITC-dextran in serum and increased FITC immunofluorescence within the 
colonic mucosa, reflecting increased epithelial permeability. In summary, our work supports a model 
where increased apoptosis caused by IR loss may contribute to barrier dysfunction and increased 
permeability that enhances inflammation after DNA damage, which could explain the increased 
inflammation-associated colon tumorigenesis observed in mice lacking IR (Figure 5.6).                   
 
Contributions of IGF1R to apoptosis and tumorigenesis in the absence of IR 
 In order to understand the consequences of IR loss on radiation-induced apoptosis and tumor 
initiation, it is necessary to understand what roles IGF1R plays during these events. IGF1R has previously 
been linked to resistance to apoptosis induced by DNA damage. Inhibition of IGF1R was shown to 
sensitize multiple cancer cells lines to apoptosis induced by radiation and chemotherapeutic agents 
345-348
. 
In vivo work using breast, gastric, and pancreatic xenografts provided further evidence that combining 
radiation and IGF1R inhibition more effectively reduced tumor growth 
349-351
. Nevertheless, the role of 
IGF1R in modulating apoptosis of non-cancerous cells in animal models has not been well explored. In 
the normal intestine, the concept that IGF1R may exert anti-apoptotic actions is supported by findings 
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that apoptosis was decreased in mice overexpressing IGF1 and increased in mice lacking IRS-1 
112,113,235
. 
However, these studies did not specifically address whether these effects were mediated by IGF1R or IR. 
Our work demonstrated that in colon, IR loss rather than IGF1R loss increased radiation-induced 
apoptosis of CECs. It is therefore possible that in the normal colon, preventing apoptosis is a 
physiological function of IR and not IGF1R. Since previous work by our group showed that local 
production of IGF1 is increased in the colon of DSS-treated mice 
352
, it could be speculated that colon 
epithelial IGF1R may, instead, play a larger role in mediating the regenerative and proliferative actions of 
IGF1 following mucosal injury 
131
. We have in hand colon histology samples from WT-IGF1R
fl/fl
 and 
VC-IGF1R
Δ/Δ
 treated with exogenous IGF1 for 5 days after 14-Gy radiation. Evaluating the degree of 
IGF1-induced crypt regeneration in the presence or absence of IGF1R should provide insight into the role 
of IGF1R in mediating colon mucosal repair. These experiments could also be performed on WT-IR
fl/fl
 
and VC-IR
Δ/Δ
 mice to define whether IGF1 signals primarily through IGF1R or IR to promote colon 
epithelial regeneration. If IGF1R is found to be essential for repair after injury caused by high dose 
radiation, the same could be true for injury caused by inflammation. Therefore, in the context of 
inflammation-induced mucosal damage, IGF1R hyperactivation in VC-IR
Δ/Δ
 mice may occur in an effort 
to heal the damaged tissue and compensate for loss of the anti-apoptotic IR. Hyperactive IGF1R 
combined with exposure to a carcinogen, like AOM, would lead to enhanced proliferation of aberrant 
cells, which will eventually favor colon tumorigenesis (Figure 5.7).    
 
Additional future studies addressing the roles of colon epithelial IR in vivo 
Generation of IEC-specific IR-B knockout mice 
 IR has been understudied in the intestine and our previous and current studies indicate that further 
research on the roles of IR in the gut are critical to understanding mechanisms of intestinal physiology 
and disease. To confirm our findings that deletion of IR in IEC enhances colon tumorigenesis, future 
studies will use WT-IR
fl/fl
 and VC-IR
Δ/Δ
 mice crossed with Apc
Min/+
 mice to test if IR loss also promotes 
formation of spontaneous colon tumors driven by a mutation that increases CRC risk in humans.  
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IR isoforms have attracted significant interest in recent years because of their potential roles in 
metabolism and cancer. To date, the availability of resources to study the individual isoforms is limited 
due to the very small difference in their mRNA and protein sequences (36 base pairs and 12 aminoacids, 
respectively). Our mouse studies on colon cancer and apoptosis suggested novel roles for IR, but the 
individual contributions of IR-A and IR-B remain unknown. In vivo or in vitro models targeting exclusive 
expression or deletion of IR-B or IR-A will be very useful to specifically delineate their roles. Transgene-
mediated expression of IR-B is one approach, potentially using the villin promoter. Disruption of only IR-
B by deleting exon 11 would directly test if expression of IR-B protects against tumors. Re-introduction 
of IR-A or IR-B in cultured VC-IR
Δ/Δ
 tumor cells is another approach, assuming we can transduce these 
cells with sufficient efficiency.  
 
Modeling obesity-associated colorectal cancer  
 Because of the current obesity epidemic and its link to increased CRC risk, the need for a good 
model of obesity-associated CRC is critical. To date, there are no animal models that successfully 
combine obesity and colon cancer. Since obesity is associated with intestinal inflammation 
66
, we used the 
DSS-AOM approach in an effort to mimic tumorigenesis that occurs in a setting of chronic inflammation, 
as occurs in obesity. However, this model is not optimal. 
Researchers have used multiple AOM injections in combination with HFD feeding, but a major 
problem with this model is that in the standard 20-week time point after the last AOM injection, animals 
do not become obese 
327,353
. Other groups used AOM treatment in the db/db genetic model of obesity and 
type 2 diabetes but chose earlier time points to assess the impact of obesity on pre-cancerous ACF and did 
not report on tumor development 
331,332
. In order to achieve obesity and significant weight gain, Tuominen 
et al. maintained mice on HFD for 9-10 months, allowing them to recover the weight they had lost 
between the start of the AOM treatment and the fourth week after the end of AOM 
327
. However, the 
authors did not measure fasting blood glucose or plasma insulin, so the insulin resistance status in these 
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mice was not clear. Furthermore, a concern about such long-term experiments is the confounding factors 
that may result from ageing.  
Genetic models of intestinal adenomas and obesity/diabetes have previously been generated by 
crossbreeding db/db mice with Apc
Min/+
 mice 
354,355
. Although animals with db/db-Apc
Min/+
 mutations 
develop significantly more small intestinal adenomas than those with Apc
Min/+ 
alone, the number of colon 
adenomas ranged between 0 and 2 per mouse 
354,355
. In a report by Algire et al., animals were fed a “high-
energy diet” and given a subcutaneous injection with a mouse colon carcinoma cell line, in order to study 
the impact of diet-induced hyperinsulinemia on tumorigenesis and, also, the beneficial effects of 
metformin 
279
. However, an important limitation of xenograft models is that tumor growth does not occur 
in the colon and the tumor microenvironment is therefore different 
356
. To overcome this issue, 
“orthotopic” models of CRC have been described, where cancer cell lines or cells from previously grown 
tumors are implanted in the submucosa of the cecum or rectum 
356-359
. Although technically challenging, 
the authors of these studies argued that these models permit rapid cancer formation and mimic human 
CRC better than subcutaneous implantation 
356-359
. Although the orthotopic approach has never been 
implemented in models of obesity, it may represent a possible option for studying obesity-associated 
CRC. A less invasive and more feasible alternative would be to colonize germ-free Apc
Min/+
 mice with gut 
microbiota from obese mice or humans and test whether microbes from obese donors increase tumors. 
Transfer of gut microbes from an obese donor to a lean host was previously shown to induce metabolic 
changes characteristic of an obese phenotype within 2-6 weeks 
360,361
. This would provide an experimental 
design that is time effective and would overcome the problem of body weight loss resulting from the 
AOM treatment. However, the problem this colonization model may face is the low tumor incidence in 
the colon.  
Overall, development of a reliable animal model of obesity-associated CRC combined with IEC-
specific deletion of IR will be a critical step in our future studies. These models would significantly 
contribute to improving our ability to study mechanisms of increased CRC risk in the growing obese 
population and should therefore be a priority in the field of gastroenterology research.  
   
104 
 
Conclusions and overall significance     
 The work presented in this dissertation highlights the importance of IR or IR isoforms in CRC 
risk, which have been under-emphasized as major focus has been centered on IGF1R. As described 
above, the larger attention given to IGF1R resulted from findings that this receptor is overexpressed in 
colon tumors and provides resistance to cancer treatments. However, our studies suggest that more 
attention should be focused on the roles of these receptors in earlier stages of colorectal neoplasia to 
better understand their contributions to CRC risk. This would ultimately lead to improved diagnosis and 
prevent progression to malignant lesions.  
A major concept emerging from the current research is that decreased IR function, particularly 
IR-B, may promote colon tumors by enhancing oncogenic actions of IGF1R, and this may be a particular 
problem during elevated insulin as occurs in obesity. The reduced IR-B expression in mouse colon tumors 
and in normal rectal mucosa of patients with adenomas and elevated plasma insulin suggest that strategies 
to maintain IR-B signaling may be beneficial preventive measures. Therefore, insulin-sensitizing drugs 
may represent good candidates for CRC prevention in obesity even before type 2 diabetes occurs. Loss of 
IR-B signaling during insulin resistance may promote compensatory IGF1R activation and predispose to 
cancer. Generation of animal models lacking IR-B will provide information on whether IR-B loss 
promotes tumorigenesis by enhancing both IGF1R and IR-A action or if the remaining IR-A is sufficient 
to attenuate IGF1R signaling. Based on our in vivo evidence that IR favors decreased apoptosis in normal 
colon epithelium, we speculate that this effect results from IR-A action, which may normally protect cells 
from apoptosis induced by environmental factors that cause DNA damage. We therefore hypothesize that, 
during colon homeostasis, IGF1R may be primarily proliferative and IR-A anti-apoptotic, while IR-B 
may act as a rheostat to attenuate the growth and anti-apoptotic actions of IGF1R and IR-A, respectively, 
and favor differentiation (Figure 5.8). During carcinogenesis in the context of obesity or insulin 
resistance, IR-B signaling may be impaired and therefore cannot limit the proliferative and anti-apoptotic 
actions of IGF1R and IR-A (Figure 5.8). This would lead to the conclusion that both IR-A and IGF1R are 
likely to contribute to tumor growth, and inhibitors targeting specifically these receptors without affecting 
   
105 
 
IR-B may represent an effective therapy for CRC 
151
. If IR-B is dysfunctional as a result of insulin 
resistance, combined IGF1R/IR-A inhibitors and insulin-sensitizing medications such as metformin 
would successfully block IGF1R/IR-A activity and promote IR-B signaling 
151
.         
     To date, most of our knowledge of the impact of the insulin/IGF pathway on intestinal growth 
come from studies focused on the small intestine 
113,129,137,138,235,290
. Our research strongly suggests that 
more studies on colon are critical in order to understand the mechanisms of colon responses to genotoxic 
stimuli, regeneration after injury, or cancer. Findings from such studies are relevant to improving 
prevention strategies or therapeutic interventions for the increased risk of CRC associated with obesity 
and type 2 diabetes. Further studies validating reduced IR-B expression in normal mucosa as a predictive 
biomarker of CRC risk could have important implications in CRC prevention and early diagnosis. Our 
epidemiological and pre-clinical work supports development of new approaches to maintain IR-B 
expression and signaling in the colonic epithelium to prevent or treat CRC, especially in obese and 
diabetic individuals who are at increased risk of CRC. 
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Figures 
 
 
Figure 5.1: Summary of key findings in the human study described in Chapter 2. 
Decreased levels of IGF1R mRNA predicted increased risk of colorectal adenomas. This may be due to 
increased endocrine or paracrine effects of IGF1, which would down-regulate IGF1R by negative 
feedback. Increased IR-A:IR-B ratio was associated with increased likelihood of having adenomas in 
patients with high plasma insulin.     
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Figure 5.2: IR-A:IR-B ratio is increased in colon tumors versus normal colon epithelium, and this is 
due to reduced IR-B mRNA. 
IR-A and IR-B mRNA levels were assessed as described in Andres et al., 2013, in normal colon epithelial 
cells (CEC) from untreated and tumors from AOM-DSS treated WT-IR
fl/fl
 mice. IR-A:IR-B ratio was 
significantly increased in tumors relative to normal CECs (26 ± 7%, P = 0.03). Qualitative analyses show 
a reduction in IR-B and maintained IR-A expression. Data are expressed as mean ± SEM (n = 4), *P < 
0.05, unpaired t-test. 
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Figure 5.3: Regulation of IR isoform pre-mRNA splicing. 
IR isoforms result from alternative pre-mRNA splicing. CUG binding protein 1 (CUGBP1) promotes 
exclusion of exon 11 and expression of IR-A. Muscleblind proteins (MBLNs) and serine/arginine-rich 
splicing factors (SRSFs) favor inclusion of exon 11 and expression of IR-B. (References: Savkur et al., 
2001, Dansithong et al., 2005, Sen et al., 2009 and 2010, Andres et al., 2013).    
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Figure 5.4: Possible mechanisms of decreased radiation-induced apoptosis during obesity, 
hyperinsulinemia, and insulin resistance. 
IGF1R activation may be enhanced in the absence of IR and mediate anti-apoptotic signals associated 
with hyperinsulinemia via increased phosphorylation of ERK or AKT. During the DNA damage response, 
AMP-activated protein kinase (AMPK) suppresses the anti-apoptotic actions of mammalian target of 
rapamycin (mTOR). However, AMPK action is decreased during insulin resistance and the resulting lack 
of mTOR inhibition may play a role in decreasing apoptosis of genetically damaged colon epithelial cells 
(CECs). It is well-established that during obesity there is a switch in the microbiota composition towards 
increased Firmicutes relative to Bacteroidetes. Firmicutes produce butyrate, which can decrease apoptosis 
in the colonic mucosa. An increase in butyrate-producer bacteria could therefore contribute to reduced 
apoptosis in obese mice. (References: Ruderman et al., 2013, Sanli et al., 2014, Pernicova et al., 2014, 
Ley et al. 2005 and 2006, Louis et al., 2009, Hass et al., 1997, Claus et al., 2003). 
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Figure 5.5: Markers of S- and M-phase are not altered by diet or IR loss 4 hours after radiation-
induced DNA damage. 
The number of cells in S-phase or M-phase in lean and obese WT-IR
fl/fl
 and VC-IR
Δ/Δ
 mice was assessed 
by histology using EdU (5-ethynyl-2'-deoxyuridine) or pH3 (phospho-histone 3) markers, respectively. 
No significant changes in the number of (A) EdU or (B) pH3 positive cells were found across groups. 
Data represent mean ± SEM (n ≥ 3 for EdU and n ≥ 4 for pH3), n.s.: no significance, two-way ANOVA.    
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Figure 5.6: Proposed model of enhanced colon tumor susceptibility resulting from increased 
apoptosis after DNA damage. 
Loss of IR leading to increased apoptosis could compromise the epithelial integrity of the colon, making 
it more permeable. This would allow components of the microbiota to penetrate the mucosa and cause 
inflammation. DNA damage in itself has been suggested to lead to inflammation via NFκB, which is 
activated by ATM (ataxia telangiectasia mutated) in response to DNA damage. Thus, inflammation as a 
result of DNA damage could be further exacerbated by IR loss. Whether IR plays a role in activation of 
NFκB is unknown. (References: Bojarski et al., 2001, Schulzke et al., 2006, Nenci et al., 2007, Kidane et 
al., 2014, Piret et al., 1999, Wu et al., 2006). 
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Figure 5.7: Proposed roles of IGF1R during inflammation-induced CRC in the absence of IR. 
In response to inflammation-induced damage to the colonic mucosa, levels of local of IGF1 are increased 
and IGF1R may be activated to initiate proliferation that leads to repair. In the absence of IR signaling, 
IGF1R becomes further activated to compensate for the loss of the anti-apoptotic actions of IR. As a 
result, colon epithelial cells acquire a hyperproliferative phenotype which, in the presence of a mutagen 
such as AOM, will enhance formation of tumors.       
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Figure 5.8: Proposed model of the roles of IGF1R, IR-A, and IR-B in normal colon physiology and 
CRC risk associated with obesity and insulin resistance. 
In order to maintain a homeostatic balance between proliferation and differentiation in the normal colon 
epithelium, IGF1R may exert primarily proliferative actions and IR-A may primarily prevent apoptosis, 
thereby favoring normal mucosal growth. On the other hand, IR-B may limit the growth-promoting and 
anti-apoptotic actions of IGF1R and IR-A to promote differentiation. During CRC risk associated with 
obesity or insulin resistance, impaired IR-B signaling may lead to a compensatory increase in 
proliferation and decrease in apoptosis through IGF1R and IR-A, respectively.  
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